Trial Outcomes & Findings for A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (NCT NCT03622593)

NCT ID: NCT03622593

Last Updated: 2025-07-11

Results Overview

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 951 participants
• Primary outcome timeframe: From Baseline through Week 56
• Results posted on: 2025-07-11

Participant Flow

Participant milestones

Measure	A: Faricimab 6 mg Q8W Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Overall Study STARTED	317	319	315
Overall Study Received at Least One Dose of Study Drug	317	319	314
Overall Study Completed up to Week 56	298	312	299
Overall Study COMPLETED	275	288	267
Overall Study NOT COMPLETED	42	31	48

Reasons for withdrawal

Measure	A: Faricimab 6 mg Q8W Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Overall Study Withdrawal by Subject	11	9	13
Overall Study Death	12	9	10
Overall Study Lost to Follow-up	11	5	8
Overall Study Adverse Event	4	5	6
Overall Study Physician Decision	2	1	6
Overall Study Other	2	2	3
Overall Study Protocol Violation	0	0	1
Overall Study Pregnancy	0	0	1

Baseline Characteristics

The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.

Baseline characteristics by cohort

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.	Total n=951 Participants Total of all reporting groups
Age, Continuous ITT Population	62.5 Years STANDARD_DEVIATION 10.1 • n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	61.6 Years STANDARD_DEVIATION 10.1 • n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	62.3 Years STANDARD_DEVIATION 10.1 • n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	62.2 Years STANDARD_DEVIATION 10.1 • n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Age, Continuous Treatment-Naive Population	62.5 Years STANDARD_DEVIATION 9.9 • n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	61.3 Years STANDARD_DEVIATION 10.3 • n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	62.5 Years STANDARD_DEVIATION 10.0 • n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	62.1 Years STANDARD_DEVIATION 10.0 • n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Sex: Female, Male ITT Population · Female	123 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	120 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	129 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	372 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Sex: Female, Male ITT Population · Male	194 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	199 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	186 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	579 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Sex: Female, Male Treatment-Naive Population · Female	100 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	94 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	97 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	291 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Sex: Female, Male Treatment-Naive Population · Male	154 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	161 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	151 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	466 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) ITT Population · Hispanic or Latino	56 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	78 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	67 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	201 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) ITT Population · Not Hispanic or Latino	252 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	232 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	240 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	724 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) ITT Population · Unknown or Not Reported	9 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	9 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	26 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) Treatment-Naive Population · Hispanic or Latino	42 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	57 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	54 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	153 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) Treatment-Naive Population · Not Hispanic or Latino	204 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	190 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	188 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	582 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Ethnicity (NIH/OMB) Treatment-Naive Population · Unknown or Not Reported	8 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	22 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · American Indian or Alaska Native	0 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · Asian	34 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	36 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	32 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	102 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · Native Hawaiian or Other Pacific Islander	2 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	2 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · Black or African American	18 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	23 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	24 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	65 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · White	250 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	249 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	253 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	752 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · More than one race	2 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) ITT Population · Unknown or Not Reported	11 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	10 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	26 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · American Indian or Alaska Native	0 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · Asian	26 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	29 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	25 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	80 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · Native Hawaiian or Other Pacific Islander	2 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	2 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · Black or African American	16 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	20 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	17 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	53 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · White	197 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	197 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	201 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	595 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · More than one race	2 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Race (NIH/OMB) Treatment-Naive Population · Unknown or Not Reported	11 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	24 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents Treatment-Naive	254 Participants n=317 Participants	255 Participants n=319 Participants	248 Participants n=315 Participants	757 Participants n=951 Participants
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents Previously Treated	63 Participants n=317 Participants	64 Participants n=319 Participants	67 Participants n=315 Participants	194 Participants n=951 Participants
Region of Enrollment ITT Population · United States and Canada	110 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	111 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	109 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	330 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Region of Enrollment ITT Population · Asia	29 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	29 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	26 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	84 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Region of Enrollment ITT Population · Rest of the World	178 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	179 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	180 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	537 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Region of Enrollment Treatment-Naive Population · United States and Canada	87 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	88 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	84 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	259 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Region of Enrollment Treatment-Naive Population · Asia	23 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	24 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	21 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	68 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Region of Enrollment Treatment-Naive Population · Rest of the World	144 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	143 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	143 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	430 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Eye Chosen as the Study Eye (Left or Right) ITT Population · Left Eye	156 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	168 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	146 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	470 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Eye Chosen as the Study Eye (Left or Right) ITT Population · Right Eye	161 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	151 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	169 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	481 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Eye Chosen as the Study Eye (Left or Right) Treatment-Naive Population · Left Eye	128 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	136 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	117 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	381 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Eye Chosen as the Study Eye (Left or Right) Treatment-Naive Population · Right Eye	126 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	119 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	131 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	376 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye ITT Population	61.9 ETDRS Letters STANDARD_DEVIATION 10.1 • n=316 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.5 ETDRS Letters STANDARD_DEVIATION 9.3 • n=317 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.1 ETDRS Letters STANDARD_DEVIATION 9.4 • n=315 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.1 ETDRS Letters STANDARD_DEVIATION 9.6 • n=948 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye Treatment-Naive Population	62.1 ETDRS Letters STANDARD_DEVIATION 10.1 • n=253 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.8 ETDRS Letters STANDARD_DEVIATION 9.3 • n=253 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.6 ETDRS Letters STANDARD_DEVIATION 9.2 • n=248 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.	62.5 ETDRS Letters STANDARD_DEVIATION 9.5 • n=754 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. 3 participants (1 in Arm A and 2 in Arm B) were excluded for missing or invalid BCVA values.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye ITT Population · ≤38 Letters	14 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	11 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	9 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	34 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye ITT Population · 39 to 63 Letters	128 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	132 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	132 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	392 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye ITT Population · ≥64 Letters	174 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	174 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	174 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	522 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye ITT Population · Missing/Invalid BCVA	1 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	2 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye Treatment-Naive Population · ≤38 Letters	10 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	23 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye Treatment-Naive Population · 39 to 63 Letters	100 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	103 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	100 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	303 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye Treatment-Naive Population · ≥64 Letters	143 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	142 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	143 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	428 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by the Baseline BCVA Letter Score Categories in the Study Eye Treatment-Naive Population · Missing/Invalid BCVA	1 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	2 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 1 - Diabetic Retinopathy (DR) Absent	2 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	4 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	7 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 2 - DR Questionable / Microaneurysms Only	3 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	10 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	19 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 3 - Mild Non-Proliferative Diabetic Retinopathy (NPDR)	90 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	92 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	94 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	276 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 4 - Moderate NPDR	88 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	72 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	79 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	239 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 5 - Moderately Severe NPDR	59 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	63 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	54 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	176 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 6 - Severe NPDR	50 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	36 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	51 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	137 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 7 - Mild Proliferative Diabetic Retinopathy (PDR)	12 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	26 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	11 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	49 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 8 - Moderate PDR	6 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	10 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	22 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 9 - High Risk PDR (DRS Level 71)	2 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 10 - High Risk PDR (DRS Level 75)	0 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 11 - Advanced PDR (DRS Level 81)	0 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · 12 - Advanced PDR (DRS Level 85)	0 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · Cannot Grade	2 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	12 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye ITT Population · Missing	3 Participants n=317 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=319 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=315 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=951 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 1 - Diabetic Retinopathy (DR) Absent	2 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 2 - DR Questionable / Microaneurysms Only	1 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	15 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 3 - Mild Non-Proliferative Diabetic Retinopathy (NPDR)	63 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	66 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	71 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	200 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 4 - Moderate NPDR	74 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	59 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	56 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	189 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 5 - Moderately Severe NPDR	48 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	56 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	43 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	147 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 6 - Severe NPDR	44 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	32 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	47 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	123 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 7 - Mild Proliferative Diabetic Retinopathy (PDR)	11 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	17 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	7 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	35 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 8 - Moderate PDR	5 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	9 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	19 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 9 - High Risk PDR (DRS Level 71)	2 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	1 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	3 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	6 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 10 - High Risk PDR (DRS Level 75)	0 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 11 - Advanced PDR (DRS Level 81)	0 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · 12 - Advanced PDR (DRS Level 85)	0 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · Cannot Grade	1 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	4 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	4 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	9 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Number of Participants by Baseline Diabetic Retinopathy Severity (DRS) Status in the Study Eye Treatment-Naive Population · Missing	3 Participants n=254 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	0 Participants n=255 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	5 Participants n=248 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.	8 Participants n=757 Participants • The ITT and Treatment-Naive (TN) Populations are grouped according to treatment assigned at randomization. The ITT Population (951) includes all global participants randomized in the study. The TN Population (757), a subset of ITT, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization.
Baseline Central Subfield Thickness in the Study Eye ITT Population	466.2 microns STANDARD_DEVIATION 119.4 • n=314 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	471.3 microns STANDARD_DEVIATION 127.0 • n=316 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	477.3 microns STANDARD_DEVIATION 129.4 • n=312 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	471.6 microns STANDARD_DEVIATION 125.3 • n=942 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.
Baseline Central Subfield Thickness in the Study Eye Treatment-Naive Population	464.6 microns STANDARD_DEVIATION 117.9 • n=251 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	473.0 microns STANDARD_DEVIATION 130.5 • n=252 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	474.3 microns STANDARD_DEVIATION 129.5 • n=248 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.	470.6 microns STANDARD_DEVIATION 126.0 • n=751 Participants • The ITT Population (951) includes all global participants randomized in the study. The Treatment-Naive Population (757), ITT subset, includes randomized participants who had not received any IVT anti-VEGF agents in the study eye before randomization. Nine participants in the ITT (3 per arm) were excluded for missing or ungradable assessments.

PRIMARY outcome

Timeframe: From Baseline through Week 56

Population: ITT Population and Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	11.8 ETDRS Letters Interval 10.6 to 13.0	10.8 ETDRS Letters Interval 9.6 to 11.9	10.3 ETDRS Letters Interval 9.1 to 11.4
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	11.7 ETDRS Letters Interval 10.4 to 13.0	11.2 ETDRS Letters Interval 9.9 to 12.4	10.5 ETDRS Letters Interval 9.2 to 11.9

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: ITT Population and Treatment-Naive Population. Only participants with non-missing, valid assessments at Baseline and Week 52 were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=231 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=251 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=238 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at Week 52, ITT and Treatment-Naive Populations ITT Population	44.2 Percentage of participants Interval 37.1 to 51.4	43.7 Percentage of participants Interval 36.8 to 50.7	46.8 Percentage of participants Interval 39.8 to 53.8
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at Week 52, ITT and Treatment-Naive Populations Treatment-Naive Population	46.9 Percentage of participants Interval 38.7 to 55.1	45.7 Percentage of participants Interval 37.8 to 53.7	52.3 Percentage of participants Interval 44.2 to 60.4

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 16	9.9 ETDRS Letters Interval 9.0 to 10.7	9.8 ETDRS Letters Interval 9.0 to 10.7	8.8 ETDRS Letters Interval 7.9 to 9.6
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 20	10.1 ETDRS Letters Interval 9.2 to 10.9	9.5 ETDRS Letters Interval 8.6 to 10.4	8.8 ETDRS Letters Interval 8.0 to 9.7
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 24	10.6 ETDRS Letters Interval 9.7 to 11.5	9.9 ETDRS Letters Interval 9.0 to 10.8	9.3 ETDRS Letters Interval 8.4 to 10.2
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 28	10.7 ETDRS Letters Interval 9.7 to 11.6	10.5 ETDRS Letters Interval 9.6 to 11.4	9.6 ETDRS Letters Interval 8.7 to 10.5
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 4	6.1 ETDRS Letters Interval 5.4 to 6.8	6.6 ETDRS Letters Interval 5.8 to 7.3	6.4 ETDRS Letters Interval 5.7 to 7.1
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 8	7.8 ETDRS Letters Interval 7.0 to 8.5	8.1 ETDRS Letters Interval 7.4 to 8.9	7.5 ETDRS Letters Interval 6.8 to 8.3
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 12	8.7 ETDRS Letters Interval 7.8 to 9.5	9.1 ETDRS Letters Interval 8.2 to 9.9	8.5 ETDRS Letters Interval 7.7 to 9.4
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 32	11.3 ETDRS Letters Interval 10.3 to 12.3	10.2 ETDRS Letters Interval 9.2 to 11.1	9.4 ETDRS Letters Interval 8.5 to 10.4
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 36	11.0 ETDRS Letters Interval 10.1 to 12.0	10.6 ETDRS Letters Interval 9.6 to 11.6	10.4 ETDRS Letters Interval 9.5 to 11.4
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 40	11.4 ETDRS Letters Interval 10.3 to 12.5	10.7 ETDRS Letters Interval 9.6 to 11.7	10.3 ETDRS Letters Interval 9.2 to 11.3
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 44	11.7 ETDRS Letters Interval 10.7 to 12.7	10.9 ETDRS Letters Interval 9.9 to 11.9	10.5 ETDRS Letters Interval 9.5 to 11.5
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 48	11.8 ETDRS Letters Interval 10.7 to 12.9	10.6 ETDRS Letters Interval 9.5 to 11.7	10.1 ETDRS Letters Interval 9.0 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 52	11.6 ETDRS Letters Interval 10.5 to 12.6	10.7 ETDRS Letters Interval 9.6 to 11.7	10.4 ETDRS Letters Interval 9.3 to 11.4
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 56	11.6 ETDRS Letters Interval 10.4 to 12.8	10.6 ETDRS Letters Interval 9.5 to 11.8	9.9 ETDRS Letters Interval 8.7 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 60	11.4 ETDRS Letters Interval 10.2 to 12.6	10.1 ETDRS Letters Interval 8.9 to 11.3	10.1 ETDRS Letters Interval 8.9 to 11.3
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 64	11.6 ETDRS Letters Interval 10.4 to 12.7	10.3 ETDRS Letters Interval 9.2 to 11.5	9.4 ETDRS Letters Interval 8.2 to 10.6
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 68	11.2 ETDRS Letters Interval 10.0 to 12.3	10.1 ETDRS Letters Interval 9.0 to 11.3	10.0 ETDRS Letters Interval 8.8 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 72	11.2 ETDRS Letters Interval 9.9 to 12.4	9.9 ETDRS Letters Interval 8.8 to 11.1	9.4 ETDRS Letters Interval 8.2 to 10.6
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 76	10.6 ETDRS Letters Interval 9.3 to 11.9	9.4 ETDRS Letters Interval 8.1 to 10.7	9.5 ETDRS Letters Interval 8.2 to 10.8
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 80	10.6 ETDRS Letters Interval 9.2 to 12.0	9.5 ETDRS Letters Interval 8.1 to 10.9	9.1 ETDRS Letters Interval 7.7 to 10.5
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 84	9.8 ETDRS Letters Interval 8.4 to 11.2	10.3 ETDRS Letters Interval 9.0 to 11.7	9.6 ETDRS Letters Interval 8.2 to 11.0
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 88	9.8 ETDRS Letters Interval 8.4 to 11.3	10.0 ETDRS Letters Interval 8.6 to 11.4	9.2 ETDRS Letters Interval 7.7 to 10.6
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 92	10.8 ETDRS Letters Interval 9.3 to 12.2	10.2 ETDRS Letters Interval 8.8 to 11.7	9.3 ETDRS Letters Interval 7.9 to 10.8
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 96	11.3 ETDRS Letters Interval 9.8 to 12.8	10.5 ETDRS Letters Interval 9.1 to 12.0	9.0 ETDRS Letters Interval 7.5 to 10.5
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population Week 100	10.7 ETDRS Letters Interval 9.1 to 12.3	9.5 ETDRS Letters Interval 7.9 to 11.0	9.8 ETDRS Letters Interval 8.2 to 11.4

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization. Participants were grouped according to the treatment assigned at randomization. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 52	11.7 ETDRS Letters Interval 10.5 to 12.8	11.1 ETDRS Letters Interval 9.9 to 12.2	10.7 ETDRS Letters Interval 9.5 to 11.9
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 4	6.0 ETDRS Letters Interval 5.2 to 6.9	6.7 ETDRS Letters Interval 5.8 to 7.5	6.3 ETDRS Letters Interval 5.4 to 7.1
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 8	7.5 ETDRS Letters Interval 6.6 to 8.4	8.2 ETDRS Letters Interval 7.3 to 9.1	7.3 ETDRS Letters Interval 6.4 to 8.2
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 12	8.7 ETDRS Letters Interval 7.8 to 9.6	9.2 ETDRS Letters Interval 8.3 to 10.1	8.5 ETDRS Letters Interval 7.6 to 9.5
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 16	9.7 ETDRS Letters Interval 8.8 to 10.7	10.0 ETDRS Letters Interval 9.1 to 10.9	8.7 ETDRS Letters Interval 7.8 to 9.6
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 20	10.0 ETDRS Letters Interval 9.1 to 11.0	9.8 ETDRS Letters Interval 8.8 to 10.7	9.0 ETDRS Letters Interval 8.1 to 10.0
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 24	10.6 ETDRS Letters Interval 9.6 to 11.6	10.2 ETDRS Letters Interval 9.2 to 11.2	9.4 ETDRS Letters Interval 8.4 to 10.4
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 28	10.8 ETDRS Letters Interval 9.8 to 11.8	10.8 ETDRS Letters Interval 9.8 to 11.8	9.9 ETDRS Letters Interval 8.9 to 10.9
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 32	11.2 ETDRS Letters Interval 10.1 to 12.3	10.3 ETDRS Letters Interval 9.2 to 11.4	9.9 ETDRS Letters Interval 8.8 to 11.0
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 36	10.8 ETDRS Letters Interval 9.7 to 11.9	10.9 ETDRS Letters Interval 9.8 to 12.0	10.5 ETDRS Letters Interval 9.3 to 11.6
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 40	11.3 ETDRS Letters Interval 10.2 to 12.5	11.2 ETDRS Letters Interval 10.0 to 12.3	10.6 ETDRS Letters Interval 9.5 to 11.8
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 44	11.5 ETDRS Letters Interval 10.4 to 12.7	11.2 ETDRS Letters Interval 10.1 to 12.3	11.1 ETDRS Letters Interval 9.9 to 12.2
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 48	11.4 ETDRS Letters Interval 10.2 to 12.7	10.9 ETDRS Letters Interval 9.7 to 12.1	10.5 ETDRS Letters Interval 9.3 to 11.7
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 56	11.4 ETDRS Letters Interval 10.0 to 12.8	11.0 ETDRS Letters Interval 9.6 to 12.3	10.0 ETDRS Letters Interval 8.6 to 11.4
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 60	11.4 ETDRS Letters Interval 10.0 to 12.7	10.5 ETDRS Letters Interval 9.2 to 11.8	10.1 ETDRS Letters Interval 8.8 to 11.5
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 64	11.6 ETDRS Letters Interval 10.2 to 12.9	10.5 ETDRS Letters Interval 9.2 to 11.8	9.5 ETDRS Letters Interval 8.2 to 10.8
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 68	11.2 ETDRS Letters Interval 9.9 to 12.5	10.3 ETDRS Letters Interval 9.0 to 11.6	10.0 ETDRS Letters Interval 8.7 to 11.3
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 72	11.1 ETDRS Letters Interval 9.7 to 12.5	10.1 ETDRS Letters Interval 8.8 to 11.5	9.6 ETDRS Letters Interval 8.2 to 10.9
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 76	10.6 ETDRS Letters Interval 9.0 to 12.1	9.7 ETDRS Letters Interval 8.2 to 11.2	9.5 ETDRS Letters Interval 8.0 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 80	10.9 ETDRS Letters Interval 9.4 to 12.5	10.0 ETDRS Letters Interval 8.5 to 11.5	9.3 ETDRS Letters Interval 7.8 to 10.9
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 84	9.9 ETDRS Letters Interval 8.4 to 11.5	10.8 ETDRS Letters Interval 9.3 to 12.3	9.6 ETDRS Letters Interval 8.0 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 88	9.6 ETDRS Letters Interval 7.9 to 11.2	10.2 ETDRS Letters Interval 8.6 to 11.8	9.4 ETDRS Letters Interval 7.8 to 11.1
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 92	10.4 ETDRS Letters Interval 8.8 to 12.1	10.6 ETDRS Letters Interval 9.0 to 12.2	9.6 ETDRS Letters Interval 7.9 to 11.2
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 96	10.6 ETDRS Letters Interval 8.9 to 12.3	10.9 ETDRS Letters Interval 9.2 to 12.5	9.0 ETDRS Letters Interval 7.3 to 10.7
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population Week 100	10.4 ETDRS Letters Interval 8.5 to 12.2	10.0 ETDRS Letters Interval 8.2 to 11.7	9.8 ETDRS Letters Interval 7.9 to 11.6

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=293 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Gaining ≥15 Letters	33.8 Percentage of participants Interval 28.4 to 39.2	28.5 Percentage of participants Interval 23.6 to 33.3	30.3 Percentage of participants Interval 25.0 to 35.5
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Gaining ≥10 Letters	59.3 Percentage of participants Interval 53.6 to 64.9	53.0 Percentage of participants Interval 47.5 to 58.5	53.9 Percentage of participants Interval 48.3 to 59.5
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Gaining ≥5 Letters	81.8 Percentage of participants Interval 77.3 to 86.4	77.4 Percentage of participants Interval 72.7 to 82.1	78.0 Percentage of participants Interval 73.3 to 82.7
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Gaining ≥0 Letters	92.1 Percentage of participants Interval 89.0 to 95.3	91.1 Percentage of participants Interval 87.8 to 94.3	91.4 Percentage of participants Interval 88.2 to 94.6

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	13.4 Percentage of participants Interval 9.9 to 17.0	10.8 Percentage of participants Interval 7.5 to 14.2	10.6 Percentage of participants Interval 7.3 to 14.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	15.2 Percentage of participants Interval 11.2 to 19.1	16.7 Percentage of participants Interval 12.7 to 20.8	15.4 Percentage of participants Interval 11.5 to 19.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	20.7 Percentage of participants Interval 16.3 to 25.1	22.1 Percentage of participants Interval 17.6 to 26.5	19.3 Percentage of participants Interval 15.0 to 23.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	24.4 Percentage of participants Interval 19.7 to 29.1	24.3 Percentage of participants Interval 19.7 to 28.8	23.1 Percentage of participants Interval 18.5 to 27.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	26.7 Percentage of participants Interval 21.8 to 31.6	21.3 Percentage of participants Interval 16.8 to 25.7	22.8 Percentage of participants Interval 18.3 to 27.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	29.8 Percentage of participants Interval 24.7 to 34.9	24.0 Percentage of participants Interval 19.3 to 28.6	24.6 Percentage of participants Interval 19.8 to 29.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	30.1 Percentage of participants Interval 25.0 to 35.3	26.7 Percentage of participants Interval 21.9 to 31.5	25.7 Percentage of participants Interval 20.7 to 30.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	35.9 Percentage of participants Interval 30.6 to 41.3	27.3 Percentage of participants Interval 22.2 to 32.3	23.9 Percentage of participants Interval 19.1 to 28.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	33.8 Percentage of participants Interval 28.5 to 39.1	32.1 Percentage of participants Interval 27.0 to 37.2	28.5 Percentage of participants Interval 23.5 to 33.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	37.8 Percentage of participants Interval 32.3 to 43.3	30.5 Percentage of participants Interval 25.4 to 35.6	29.1 Percentage of participants Interval 24.0 to 34.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	37.1 Percentage of participants Interval 31.6 to 42.5	30.1 Percentage of participants Interval 25.0 to 32.5	33.4 Percentage of participants Interval 28.0 to 38.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	33.0 Percentage of participants Interval 27.5 to 38.6	29.4 Percentage of participants Interval 24.4 to 34.3	29.3 Percentage of participants Interval 24.1 to 34.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	35.0 Percentage of participants Interval 29.6 to 40.4	31.0 Percentage of participants Interval 25.9 to 36.2	33.1 Percentage of participants Interval 27.7 to 38.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	38.8 Percentage of participants Interval 33.2 to 44.3	29.5 Percentage of participants Interval 24.5 to 34.6	36.4 Percentage of participants Interval 30.7 to 42.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	38.0 Percentage of participants Interval 32.3 to 43.7	30.3 Percentage of participants Interval 25.2 to 35.5	36.6 Percentage of participants Interval 30.9 to 42.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	40.3 Percentage of participants Interval 34.7 to 45.9	29.6 Percentage of participants Interval 24.5 to 34.8	31.9 Percentage of participants Interval 26.5 to 37.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	36.9 Percentage of participants Interval 31.3 to 42.5	31.1 Percentage of participants Interval 25.8 to 36.5	35.4 Percentage of participants Interval 29.8 to 41.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	36.8 Percentage of participants Interval 31.0 to 42.6	30.5 Percentage of participants Interval 25.1 to 35.8	32.5 Percentage of participants Interval 26.9 to 38.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	37.1 Percentage of participants Interval 31.5 to 42.7	31.2 Percentage of participants Interval 25.9 to 36.6	35.1 Percentage of participants Interval 29.4 to 40.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	39.6 Percentage of participants Interval 33.8 to 45.5	30.1 Percentage of participants Interval 24.8 to 35.3	35.3 Percentage of participants Interval 29.6 to 41.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	38.5 Percentage of participants Interval 32.9 to 44.2	30.6 Percentage of participants Interval 25.2 to 36.0	38.1 Percentage of participants Interval 32.4 to 43.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	40.4 Percentage of participants Interval 34.7 to 46.1	29.6 Percentage of participants Interval 24.3 to 35.0	38.5 Percentage of participants Interval 32.6 to 44.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	42.3 Percentage of participants Interval 36.4 to 48.1	34.6 Percentage of participants Interval 29.2 to 40.0	42.1 Percentage of participants Interval 36.0 to 48.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	44.2 Percentage of participants Interval 38.1 to 50.2	34.4 Percentage of participants Interval 29.0 to 39.7	36.0 Percentage of participants Interval 30.1 to 41.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	43.1 Percentage of participants Interval 37.1 to 49.1	31.2 Percentage of participants Interval 25.9 to 36.5	40.8 Percentage of participants Interval 34.8 to 46.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	44.8 Percentage of participants Interval 39.3 to 50.2	46.9 Percentage of participants Interval 41.4 to 52.4	43.2 Percentage of participants Interval 37.7 to 48.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	52.5 Percentage of participants Interval 46.9 to 58.0	51.3 Percentage of participants Interval 45.9 to 56.7	41.8 Percentage of participants Interval 36.3 to 47.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	54.0 Percentage of participants Interval 48.6 to 59.5	50.0 Percentage of participants Interval 44.5 to 55.6	45.5 Percentage of participants Interval 40.0 to 51.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	57.0 Percentage of participants Interval 51.5 to 62.5	52.8 Percentage of participants Interval 47.4 to 58.3	48.4 Percentage of participants Interval 42.9 to 53.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	58.3 Percentage of participants Interval 52.7 to 63.9	51.3 Percentage of participants Interval 45.8 to 56.8	51.7 Percentage of participants Interval 46.1 to 57.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	60.1 Percentage of participants Interval 54.4 to 65.8	50.9 Percentage of participants Interval 45.2 to 56.6	52.5 Percentage of participants Interval 46.8 to 58.1
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	58.6 Percentage of participants Interval 52.9 to 64.2	57.3 Percentage of participants Interval 51.7 to 62.9	58.7 Percentage of participants Interval 53.0 to 64.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	61.8 Percentage of participants Interval 56.2 to 67.4	56.0 Percentage of participants Interval 50.5 to 61.6	55.8 Percentage of participants Interval 50.2 to 61.4
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	62.0 Percentage of participants Interval 56.3 to 67.6	55.9 Percentage of participants Interval 50.3 to 61.5	57.2 Percentage of participants Interval 51.6 to 62.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	58.0 Percentage of participants Interval 52.1 to 63.9	56.7 Percentage of participants Interval 51.1 to 62.2	56.3 Percentage of participants Interval 50.7 to 61.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	61.1 Percentage of participants Interval 55.4 to 66.8	58.7 Percentage of participants Interval 53.1 to 64.3	57.1 Percentage of participants Interval 51.4 to 62.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	60.7 Percentage of participants Interval 55.1 to 66.4	55.9 Percentage of participants Interval 50.3 to 61.5	56.2 Percentage of participants Interval 50.4 to 62.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	58.5 Percentage of participants Interval 52.7 to 64.4	53.7 Percentage of participants Interval 48.1 to 59.4	57.0 Percentage of participants Interval 51.0 to 63.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	59.7 Percentage of participants Interval 53.8 to 65.5	54.5 Percentage of participants Interval 48.9 to 60.1	51.5 Percentage of participants Interval 45.6 to 57.4
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	60.2 Percentage of participants Interval 54.5 to 66.0	54.1 Percentage of participants Interval 48.3 to 60.0	60.7 Percentage of participants Interval 54.8 to 66.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	59.2 Percentage of participants Interval 53.1 to 62.5	55.6 Percentage of participants Interval 49.8 to 61.4	56.6 Percentage of participants Interval 50.7 to 62.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	58.7 Percentage of participants Interval 52.9 to 64.6	52.5 Percentage of participants Interval 46.7 to 58.3	57.0 Percentage of participants Interval 51.0 to 62.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	59.6 Percentage of participants Interval 53.6 to 65.6	55.0 Percentage of participants Interval 49.2 to 60.7	56.5 Percentage of participants Interval 50.4 to 62.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	56.2 Percentage of participants Interval 50.3 to 62.1	53.3 Percentage of participants Interval 47.5 to 59.1	55.8 Percentage of participants Interval 49.8 to 61.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	58.3 Percentage of participants Interval 52.4 to 64.1	53.5 Percentage of participants Interval 47.6 to 59.5	57.0 Percentage of participants Interval 51.0 to 63.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	59.5 Percentage of participants Interval 53.6 to 65.4	55.0 Percentage of participants Interval 49.2 to 60.8	58.5 Percentage of participants Interval 52.5 to 64.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	65.4 Percentage of participants Interval 59.5 to 71.2	58.0 Percentage of participants Interval 52.1 to 63.8	58.8 Percentage of participants Interval 52.6 to 64.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	63.7 Percentage of participants Interval 58.0 to 69.3	54.0 Percentage of participants Interval 48.2 to 59.9	65.3 Percentage of participants Interval 59.5 to 71.2
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	29.1 Percentage of participants Interval 24.2 to 34.0	26.9 Percentage of participants Interval 22.1 to 31.8	28.7 Percentage of participants Interval 23.8 to 33.6
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	39.7 Percentage of participants Interval 34.4 to 45.1	41.4 Percentage of participants Interval 36.0 to 46.9	34.8 Percentage of participants Interval 29.6 to 40.0

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	57.8 Percentage of participants Interval 52.3 to 63.2	61.8 Percentage of participants Interval 56.4 to 67.2	59.2 Percentage of participants Interval 53.7 to 64.6
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	67.0 Percentage of participants Interval 61.9 to 72.2	68.8 Percentage of participants Interval 63.7 to 73.9	66.0 Percentage of participants Interval 60.7 to 71.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	70.9 Percentage of participants Interval 65.9 to 76.0	74.3 Percentage of participants Interval 69.4 to 79.2	72.5 Percentage of participants Interval 67.4 to 77.5
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	75.4 Percentage of participants Interval 70.6 to 80.2	74.6 Percentage of participants Interval 69.9 to 79.4	69.6 Percentage of participants Interval 64.4 to 74.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	76.0 Percentage of participants Interval 71.2 to 80.8	79.5 Percentage of participants Interval 75.1 to 84.0	71.4 Percentage of participants Interval 66.3 to 76.6
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	78.3 Percentage of participants Interval 73.7 to 83.0	76.3 Percentage of participants Interval 71.6 to 80.9	72.2 Percentage of participants Interval 67.2 to 77.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	76.8 Percentage of participants Interval 72.0 to 81.7	79.4 Percentage of participants Interval 74.8 to 83.9	77.2 Percentage of participants Interval 72.4 to 81.9
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	80.0 Percentage of participants Interval 75.4 to 84.6	78.3 Percentage of participants Interval 73.6 to 83.0	75.9 Percentage of participants Interval 70.9 to 80.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	79.0 Percentage of participants Interval 74.2 to 83.8	80.0 Percentage of participants Interval 75.4 to 84.6	78.4 Percentage of participants Interval 73.7 to 83.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	79.5 Percentage of participants Interval 74.8 to 84.2	78.0 Percentage of participants Interval 73.2 to 82.7	79.8 Percentage of participants Interval 75.1 to 84.5
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	84.0 Percentage of participants Interval 79.7 to 88.3	77.5 Percentage of participants Interval 72.8 to 82.3	81.9 Percentage of participants Interval 77.5 to 86.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	81.3 Percentage of participants Interval 76.7 to 86.0	81.5 Percentage of participants Interval 77.1 to 85.9	77.2 Percentage of participants Interval 72.4 to 82.0
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	81.7 Percentage of participants Interval 77.1 to 86.3	78.2 Percentage of participants Interval 73.5 to 83.0	77.1 Percentage of participants Interval 72.2 to 82.0
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	78.6 Percentage of participants Interval 73.8 to 83.4	79.2 Percentage of participants Interval 74.5 to 83.8	80.3 Percentage of participants Interval 75.7 to 84.9
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	75.7 Percentage of participants Interval 70.5 to 80.8	75.9 Percentage of participants Interval 71.0 to 80.9	80.3 Percentage of participants Interval 75.4 to 85.1
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	77.6 Percentage of participants Interval 72.6 to 82.6	77.3 Percentage of participants Interval 72.5 to 82.0	72.5 Percentage of participants Interval 67.2 to 77.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	77.0 Percentage of participants Interval 72.0 to 82.1	76.0 Percentage of participants Interval 70.9 to 81.0	78.5 Percentage of participants Interval 73.5 to 83.4
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	79.5 Percentage of participants Interval 74.5 to 84.4	76.7 Percentage of participants Interval 71.6 to 81.7	76.1 Percentage of participants Interval 70.8 to 81.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	75.6 Percentage of participants Interval 70.5 to 80.8	73.8 Percentage of participants Interval 68.7 to 78.9	72.6 Percentage of participants Interval 67.1 to 78.0
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	74.9 Percentage of participants Interval 69.7 to 80.2	75.4 Percentage of participants Interval 70.3 to 80.5	77.4 Percentage of participants Interval 72.2 to 82.5
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	73.1 Percentage of participants Interval 67.7 to 78.4	79.9 Percentage of participants Interval 75.2 to 84.7	75.2 Percentage of participants Interval 70.0 to 80.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	74.2 Percentage of participants Interval 69.0 to 79.5	74.3 Percentage of participants Interval 69.2 to 79.5	77.5 Percentage of participants Interval 72.4 to 82.6
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	76.5 Percentage of participants Interval 71.3 to 81.7	76.6 Percentage of participants Interval 71.6 to 81.6	77.4 Percentage of participants Interval 72.2 to 82.6
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	80.9 Percentage of participants Interval 76.1 to 85.7	76.2 Percentage of participants Interval 71.2 to 81.2	76.0 Percentage of participants Interval 70.7 to 81.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	80.0 Percentage of participants Interval 75.1 to 84.8	75.3 Percentage of participants Interval 70.3 to 80.4	81.3 Percentage of participants Interval 76.3 to 86.2

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	85.1 Percentage of participants Interval 81.2 to 89.0	89.2 Percentage of participants Interval 85.8 to 92.7	89.3 Percentage of participants Interval 85.9 to 92.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	90.2 Percentage of participants Interval 86.9 to 93.5	91.3 Percentage of participants Interval 88.2 to 94.4	90.3 Percentage of participants Interval 87.0 to 93.6
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	90.8 Percentage of participants Interval 87.6 to 94.0	92.7 Percentage of participants Interval 89.8 to 95.6	90.4 Percentage of participants Interval 87.1 to 93.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	92.4 Percentage of participants Interval 89.4 to 95.3	91.1 Percentage of participants Interval 88.0 to 94.3	90.9 Percentage of participants Interval 87.7 to 94.1
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	92.2 Percentage of participants Interval 89.1 to 95.3	91.7 Percentage of participants Interval 88.6 to 94.8	93.9 Percentage of participants Interval 91.2 to 96.6
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	91.5 Percentage of participants Interval 88.3 to 94.7	91.5 Percentage of participants Interval 88.5 to 94.6	91.5 Percentage of participants Interval 88.4 to 94.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	92.2 Percentage of participants Interval 89.1 to 95.4	94.3 Percentage of participants Interval 91.7 to 96.8	94.0 Percentage of participants Interval 91.4 to 96.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	91.4 Percentage of participants Interval 88.2 to 94.7	90.9 Percentage of participants Interval 87.6 to 94.2	92.8 Percentage of participants Interval 89.8 to 95.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	92.4 Percentage of participants Interval 89.3 to 95.5	90.5 Percentage of participants Interval 87.1 to 93.8	95.0 Percentage of participants Interval 92.5 to 97.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	92.0 Percentage of participants Interval 88.8 to 95.2	92.3 Percentage of participants Interval 89.3 to 95.4	93.1 Percentage of participants Interval 90.1 to 96.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	91.8 Percentage of participants Interval 88.5 to 95.1	91.2 Percentage of participants Interval 88.0 to 94.5	92.6 Percentage of participants Interval 89.6 to 95.6
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	93.7 Percentage of participants Interval 90.7 to 96.7	91.0 Percentage of participants Interval 87.7 to 94.3	91.4 Percentage of participants Interval 88.2 to 94.6
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	93.6 Percentage of participants Interval 90.7 to 96.5	90.4 Percentage of participants Interval 86.9 to 93.8	91.9 Percentage of participants Interval 88.7 to 95.1
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	92.7 Percentage of participants Interval 89.6 to 95.7	91.5 Percentage of participants Interval 88.3 to 94.7	90.9 Percentage of participants Interval 87.5 to 94.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	89.3 Percentage of participants Interval 85.6 to 93.0	88.5 Percentage of participants Interval 84.9 to 92.2	92.6 Percentage of participants Interval 89.5 to 95.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	91.3 Percentage of participants Interval 87.9 to 94.6	89.7 Percentage of participants Interval 86.2 to 93.2	87.4 Percentage of participants Interval 83.4 to 91.4
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	89.4 Percentage of participants Interval 85.6 to 93.2	90.5 Percentage of participants Interval 87.0 to 94.0	91.3 Percentage of participants Interval 87.8 to 94.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	89.1 Percentage of participants Interval 85.2 to 93.0	90.4 Percentage of participants Interval 86.8 to 94.0	88.4 Percentage of participants Interval 84.5 to 92.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	89.6 Percentage of participants Interval 86.0 to 93.3	86.3 Percentage of participants Interval 82.3 to 90.3	90.3 Percentage of participants Interval 86.7 to 94.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	86.6 Percentage of participants Interval 82.5 to 90.8	88.5 Percentage of participants Interval 84.7 to 92.3	88.6 Percentage of participants Interval 84.6 to 92.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	87.1 Percentage of participants Interval 83.0 to 91.2	90.2 Percentage of participants Interval 86.7 to 93.7	87.9 Percentage of participants Interval 83.9 to 91.9
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	84.4 Percentage of participants Interval 80.0 to 88.9	89.5 Percentage of participants Interval 85.9 to 93.1	88.1 Percentage of participants Interval 84.1 to 92.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	86.7 Percentage of participants Interval 82.5 to 90.9	86.7 Percentage of participants Interval 82.6 to 90.7	87.1 Percentage of participants Interval 82.9 to 91.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	86.5 Percentage of participants Interval 82.3 to 90.7	87.0 Percentage of participants Interval 83.0 to 91.0	89.1 Percentage of participants Interval 85.2 to 93.1
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	86.1 Percentage of participants Interval 81.8 to 90.3	87.5 Percentage of participants Interval 83.7 to 91.4	91.1 Percentage of participants Interval 87.5 to 94.7

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: Treatment-Naive Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization. Participants were grouped according to the treatment assigned at randomization. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=208 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=231 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=213 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Gaining ≥15 Letters	32.9 Percentage of participants Interval 26.7 to 39.0	29.4 Percentage of participants Interval 23.9 to 34.9	32.7 Percentage of participants Interval 26.5 to 38.8
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Gaining ≥10 Letters	58.3 Percentage of participants Interval 51.8 to 64.8	55.5 Percentage of participants Interval 49.3 to 61.7	56.1 Percentage of participants Interval 49.6 to 62.5
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Gaining ≥5 Letters	81.8 Percentage of participants Interval 76.5 to 87.0	79.6 Percentage of participants Interval 74.5 to 84.7	80.6 Percentage of participants Interval 75.4 to 85.8
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Gaining ≥0 Letters	93.2 Percentage of participants Interval 89.8 to 96.7	92.2 Percentage of participants Interval 88.8 to 95.6	92.0 Percentage of participants Interval 88.4 to 95.6

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	13.9 Percentage of participants Interval 9.7 to 18.0	10.7 Percentage of participants Interval 7.0 to 14.4	10.3 Percentage of participants Interval 6.6 to 14.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	14.7 Percentage of participants Interval 10.3 to 19.1	17.9 Percentage of participants Interval 13.2 to 22.5	15.7 Percentage of participants Interval 11.2 to 20.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	19.9 Percentage of participants Interval 15.0 to 24.8	23.2 Percentage of participants Interval 18.1 to 28.3	19.7 Percentage of participants Interval 14.8 to 24.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	23.3 Percentage of participants Interval 18.0 to 28.5	26.0 Percentage of participants Interval 20.8 to 31.2	23.5 Percentage of participants Interval 18.2 to 28.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	25.9 Percentage of participants Interval 20.4 to 31.4	22.7 Percentage of participants Interval 17.5 to 27.9	22.0 Percentage of participants Interval 16.9 to 27.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	30.2 Percentage of participants Interval 24.4 to 35.9	24.5 Percentage of participants Interval 19.2 to 29.7	24.3 Percentage of participants Interval 18.9 to 29.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	29.8 Percentage of participants Interval 23.9 to 35.6	28.3 Percentage of participants Interval 22.7 to 33.8	26.5 Percentage of participants Interval 20.8 to 32.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	34.4 Percentage of participants Interval 28.4 to 40.5	27.9 Percentage of participants Interval 22.1 to 33.6	25.1 Percentage of participants Interval 19.6 to 30.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	34.1 Percentage of participants Interval 28.0 to 40.2	34.2 Percentage of participants Interval 28.3 to 40.1	28.9 Percentage of participants Interval 23.2 to 34.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	37.8 Percentage of participants Interval 31.4 to 44.1	32.5 Percentage of participants Interval 26.6 to 38.4	28.4 Percentage of participants Interval 22.6 to 34.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	36.1 Percentage of participants Interval 29.9 to 42.3	30.4 Percentage of participants Interval 24.6 to 36.2	35.0 Percentage of participants Interval 28.7 to 41.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	32.8 Percentage of participants Interval 26.4 to 39.2	31.2 Percentage of participants Interval 25.5 to 36.9	31.7 Percentage of participants Interval 25.7 to 37.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	34.1 Percentage of participants Interval 27.9 to 40.3	32.7 Percentage of participants Interval 26.9 to 38.6	33.9 Percentage of participants Interval 27.7 to 40.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	39.2 Percentage of participants Interval 33.0 to 45.5	30.6 Percentage of participants Interval 24.8 to 36.3	37.6 Percentage of participants Interval 31.1 to 44.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	37.4 Percentage of participants Interval 31.0 to 43.7	32.5 Percentage of participants Interval 26.5 to 38.4	36.2 Percentage of participants Interval 29.9 to 42.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	39.8 Percentage of participants Interval 33.5 to 46.1	31.1 Percentage of participants Interval 25.2 to 37.0	31.9 Percentage of participants Interval 25.8 to 38.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	36.0 Percentage of participants Interval 29.7 to 42.3	33.4 Percentage of participants Interval 27.2 to 39.7	36.4 Percentage of participants Interval 30.0 to 42.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	35.1 Percentage of participants Interval 28.5 to 41.6	33.7 Percentage of participants Interval 27.5 to 39.9	34.7 Percentage of participants Interval 28.2 to 41.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	37.2 Percentage of participants Interval 30.9 to 43.6	32.5 Percentage of participants Interval 26.4 to 38.6	34.5 Percentage of participants Interval 28.0 to 40.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	40.1 Percentage of participants Interval 33.5 to 46.8	33.8 Percentage of participants Interval 27.6 to 40.0	37.0 Percentage of participants Interval 30.5 to 43.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	40.1 Percentage of participants Interval 33.6 to 46.6	32.0 Percentage of participants Interval 25.9 to 38.1	39.4 Percentage of participants Interval 32.8 to 45.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	39.5 Percentage of participants Interval 32.9 to 46.1	29.9 Percentage of participants Interval 23.8 to 35.9	38.4 Percentage of participants Interval 31.8 to 45.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	42.8 Percentage of participants Interval 36.1 to 49.6	38.0 Percentage of participants Interval 31.7 to 44.2	42.5 Percentage of participants Interval 35.6 to 49.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	42.9 Percentage of participants Interval 36.1 to 49.7	35.9 Percentage of participants Interval 29.8 to 41.9	35.9 Percentage of participants Interval 29.2 to 42.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	43.9 Percentage of participants Interval 37.1 to 50.8	33.0 Percentage of participants Interval 26.9 to 39.0	40.9 Percentage of participants Interval 34.0 to 47.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	29.4 Percentage of participants Interval 23.9 to 34.9	28.9 Percentage of participants Interval 23.3 to 34.5	26.9 Percentage of participants Interval 21.3 to 32.4
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	38.2 Percentage of participants Interval 32.3 to 44.1	42.2 Percentage of participants Interval 36.1 to 48.3	33.1 Percentage of participants Interval 27.2 to 38.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	45.2 Percentage of participants Interval 39.0 to 51.4	46.9 Percentage of participants Interval 40.7 to 53.1	43.9 Percentage of participants Interval 37.7 to 50.1
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	52.3 Percentage of participants Interval 46.2 to 58.5	51.4 Percentage of participants Interval 45.4 to 57.4	41.7 Percentage of participants Interval 35.5 to 48.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	53.4 Percentage of participants Interval 47.2 to 59.6	51.1 Percentage of participants Interval 44.9 to 57.4	45.5 Percentage of participants Interval 39.2 to 51.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	57.8 Percentage of participants Interval 51.6 to 64.1	53.1 Percentage of participants Interval 46.9 to 59.2	49.3 Percentage of participants Interval 43.1 to 55.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	59.7 Percentage of participants Interval 53.4 to 66.1	53.1 Percentage of participants Interval 46.9 to 59.4	55.3 Percentage of participants Interval 49.0 to 61.6
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	61.2 Percentage of participants Interval 54.7 to 67.6	50.6 Percentage of participants Interval 44.2 to 57.1	55.7 Percentage of participants Interval 49.2 to 62.1
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	58.8 Percentage of participants Interval 52.3 to 65.2	57.8 Percentage of participants Interval 51.5 to 64.0	59.6 Percentage of participants Interval 53.1 to 66.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	61.3 Percentage of participants Interval 55.0 to 67.7	56.8 Percentage of participants Interval 50.6 to 63.1	58.5 Percentage of participants Interval 52.2 to 64.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	61.6 Percentage of participants Interval 55.0 to 68.2	56.8 Percentage of participants Interval 50.5 to 63.1	61.1 Percentage of participants Interval 54.7 to 67.4
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	57.4 Percentage of participants Interval 50.6 to 64.2	58.0 Percentage of participants Interval 51.7 to 64.2	58.1 Percentage of participants Interval 51.7 to 64.6
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	60.9 Percentage of participants Interval 54.4 to 67.4	61.6 Percentage of participants Interval 55.3 to 67.8	60.0 Percentage of participants Interval 53.5 to 66.5
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	61.0 Percentage of participants Interval 54.6 to 67.4	58.6 Percentage of participants Interval 52.3 to 64.9	58.6 Percentage of participants Interval 51.9 to 65.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	57.9 Percentage of participants Interval 51.3 to 64.5	57.1 Percentage of participants Interval 50.8 to 63.5	56.2 Percentage of participants Interval 49.5 to 63.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	58.4 Percentage of participants Interval 51.8 to 65.0	56.2 Percentage of participants Interval 49.9 to 62.5	53.7 Percentage of participants Interval 46.9 to 60.4
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	58.9 Percentage of participants Interval 52.4 to 65.4	54.4 Percentage of participants Interval 47.8 to 61.0	60.7 Percentage of participants Interval 54.0 to 67.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	58.4 Percentage of participants Interval 51.5 to 65.4	57.5 Percentage of participants Interval 51.0 to 64.1	59.3 Percentage of participants Interval 52.5 to 66.0
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	58.2 Percentage of participants Interval 51.5 to 64.9	54.0 Percentage of participants Interval 47.5 to 60.6	57.5 Percentage of participants Interval 50.8 to 64.3
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	60.4 Percentage of participants Interval 53.6 to 67.2	58.1 Percentage of participants Interval 51.6 to 64.6	57.0 Percentage of participants Interval 50.2 to 63.9
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	55.9 Percentage of participants Interval 49.1 to 62.8	56.5 Percentage of participants Interval 50.0 to 63.1	57.1 Percentage of participants Interval 50.3 to 63.8
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	57.1 Percentage of participants Interval 50.3 to 63.9	53.6 Percentage of participants Interval 46.9 to 60.3	58.8 Percentage of participants Interval 52.0 to 65.6
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	58.8 Percentage of participants Interval 51.9 to 65.6	57.0 Percentage of participants Interval 50.4 to 63.5	60.5 Percentage of participants Interval 53.7 to 67.2
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	64.7 Percentage of participants Interval 58.0 to 71.4	58.4 Percentage of participants Interval 51.9 to 65.0	59.8 Percentage of participants Interval 52.9 to 66.7
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	63.0 Percentage of participants Interval 56.5 to 69.5	55.2 Percentage of participants Interval 48.7 to 61.7	66.2 Percentage of participants Interval 59.5 to 72.8

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	57.9 Percentage of participants Interval 51.8 to 64.1	62.2 Percentage of participants Interval 56.1 to 68.3	58.3 Percentage of participants Interval 52.1 to 64.5
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	65.6 Percentage of participants Interval 59.7 to 71.4	68.3 Percentage of participants Interval 62.5 to 74.1	65.3 Percentage of participants Interval 59.3 to 71.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	71.1 Percentage of participants Interval 65.4 to 76.8	74.7 Percentage of participants Interval 69.2 to 80.2	72.4 Percentage of participants Interval 66.7 to 78.1
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	76.4 Percentage of participants Interval 71.1 to 81.7	75.5 Percentage of participants Interval 70.1 to 80.8	69.1 Percentage of participants Interval 63.2 to 75.1
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	76.5 Percentage of participants Interval 71.1 to 81.9	80.4 Percentage of participants Interval 75.4 to 85.3	72.5 Percentage of participants Interval 66.8 to 78.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	78.0 Percentage of participants Interval 72.7 to 83.3	77.4 Percentage of participants Interval 72.2 to 82.6	72.2 Percentage of participants Interval 66.5 to 77.9
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	77.2 Percentage of participants Interval 71.7 to 82.7	79.7 Percentage of participants Interval 74.6 to 84.9	76.9 Percentage of participants Interval 71.5 to 82.3
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	81.1 Percentage of participants Interval 75.9 to 86.3	80.0 Percentage of participants Interval 74.8 to 85.3	77.1 Percentage of participants Interval 71.6 to 82.6
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	77.4 Percentage of participants Interval 71.8 to 83.0	81.4 Percentage of participants Interval 76.2 to 86.5	79.3 Percentage of participants Interval 73.9 to 84.7
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	78.6 Percentage of participants Interval 73.1 to 84.0	79.7 Percentage of participants Interval 74.4 to 85.0	81.5 Percentage of participants Interval 76.2 to 86.7
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	83.7 Percentage of participants Interval 78.7 to 88.6	79.3 Percentage of participants Interval 74.0 to 84.5	85.8 Percentage of participants Interval 81.1 to 90.5
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	79.9 Percentage of participants Interval 74.4 to 85.4	84.0 Percentage of participants Interval 79.2 to 88.7	79.0 Percentage of participants Interval 73.6 to 84.4
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	81.8 Percentage of participants Interval 76.6 to 87.0	80.3 Percentage of participants Interval 75.1 to 85.4	79.4 Percentage of participants Interval 73.9 to 84.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	78.2 Percentage of participants Interval 72.7 to 83.7	78.7 Percentage of participants Interval 73.4 to 84.0	82.4 Percentage of participants Interval 77.2 to 87.7
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	75.1 Percentage of participants Interval 69.4 to 80.9	77.3 Percentage of participants Interval 71.8 to 82.8	80.3 Percentage of participants Interval 74.8 to 85.7
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	76.3 Percentage of participants Interval 70.5 to 82.1	79.0 Percentage of participants Interval 73.7 to 84.2	73.0 Percentage of participants Interval 66.9 to 79.0
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	75.4 Percentage of participants Interval 69.6 to 81.3	77.6 Percentage of participants Interval 72.0 to 83.2	78.2 Percentage of participants Interval 72.6 to 83.9
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	78.4 Percentage of participants Interval 72.8 to 84.1	77.7 Percentage of participants Interval 72.1 to 83.4	77.3 Percentage of participants Interval 71.5 to 83.1
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	75.6 Percentage of participants Interval 69.7 to 81.5	76.1 Percentage of participants Interval 70.4 to 81.7	73.6 Percentage of participants Interval 67.5 to 79.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	75.2 Percentage of participants Interval 69.3 to 81.1	78.2 Percentage of participants Interval 72.6 to 83.8	78.5 Percentage of participants Interval 72.7 to 84.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	72.3 Percentage of participants Interval 66.1 to 78.5	80.5 Percentage of participants Interval 75.2 to 85.9	76.3 Percentage of participants Interval 70.5 to 82.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	73.9 Percentage of participants Interval 67.8 to 80.0	75.9 Percentage of participants Interval 70.2 to 81.7	80.6 Percentage of participants Interval 75.1 to 86.2
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	73.7 Percentage of participants Interval 67.6 to 79.9	77.4 Percentage of participants Interval 71.8 to 83.0	80.2 Percentage of participants Interval 74.5 to 85.9
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	78.7 Percentage of participants Interval 73.0 to 84.4	77.5 Percentage of participants Interval 72.0 to 83.0	76.9 Percentage of participants Interval 70.9 to 82.8
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	79.0 Percentage of participants Interval 73.4 to 84.6	78.2 Percentage of participants Interval 72.7 to 83.7	81.7 Percentage of participants Interval 76.2 to 87.3

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	84.9 Percentage of participants Interval 80.5 to 89.3	88.5 Percentage of participants Interval 84.5 to 92.5	88.8 Percentage of participants Interval 84.9 to 92.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	89.3 Percentage of participants Interval 85.4 to 93.1	90.6 Percentage of participants Interval 87.0 to 94.2	90.1 Percentage of participants Interval 86.3 to 93.9
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	90.1 Percentage of participants Interval 86.4 to 93.9	92.9 Percentage of participants Interval 89.7 to 96.1	90.6 Percentage of participants Interval 86.9 to 94.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	91.3 Percentage of participants Interval 87.7 to 94.8	90.9 Percentage of participants Interval 87.3 to 94.5	91.3 Percentage of participants Interval 87.7 to 94.9
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	91.9 Percentage of participants Interval 88.4 to 95.4	92.9 Percentage of participants Interval 89.6 to 96.1	93.9 Percentage of participants Interval 90.9 to 97.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	90.9 Percentage of participants Interval 87.3 to 94.6	92.6 Percentage of participants Interval 89.3 to 95.9	92.2 Percentage of participants Interval 88.7 to 95.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	91.9 Percentage of participants Interval 88.4 to 95.5	95.2 Percentage of participants Interval 92.5 to 98.0	94.5 Percentage of participants Interval 91.6 to 97.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	91.2 Percentage of participants Interval 87.4 to 95.0	90.5 Percentage of participants Interval 86.6 to 94.4	93.5 Percentage of participants Interval 90.2 to 96.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	91.5 Percentage of participants Interval 87.8 to 95.3	90.5 Percentage of participants Interval 86.7 to 94.4	96.2 Percentage of participants Interval 93.7 to 98.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	91.6 Percentage of participants Interval 87.9 to 95.3	92.8 Percentage of participants Interval 89.5 to 96.2	94.8 Percentage of participants Interval 91.9 to 97.8
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	91.8 Percentage of participants Interval 88.1 to 95.6	91.5 Percentage of participants Interval 87.8 to 95.1	95.3 Percentage of participants Interval 92.4 to 98.1
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	93.5 Percentage of participants Interval 90.0 to 96.9	91.1 Percentage of participants Interval 87.5 to 94.8	92.9 Percentage of participants Interval 89.4 to 96.4
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	94.3 Percentage of participants Interval 91.1 to 97.4	91.0 Percentage of participants Interval 87.3 to 94.8	93.3 Percentage of participants Interval 89.9 to 96.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	93.9 Percentage of participants Interval 90.7 to 97.1	92.4 Percentage of participants Interval 89.0 to 95.9	91.0 Percentage of participants Interval 87.1 to 95.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	88.5 Percentage of participants Interval 84.2 to 92.8	87.8 Percentage of participants Interval 83.4 to 92.1	93.0 Percentage of participants Interval 89.5 to 96.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	90.5 Percentage of participants Interval 86.5 to 94.4	89.5 Percentage of participants Interval 85.5 to 93.5	88.5 Percentage of participants Interval 84.1 to 92.9
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	89.6 Percentage of participants Interval 85.4 to 93.8	90.7 Percentage of participants Interval 86.8 to 94.6	90.5 Percentage of participants Interval 86.4 to 94.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	89.1 Percentage of participants Interval 84.7 to 93.5	89.7 Percentage of participants Interval 85.6 to 93.9	87.7 Percentage of participants Interval 83.1 to 92.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	89.6 Percentage of participants Interval 85.5 to 93.8	88.5 Percentage of participants Interval 84.2 to 92.7	89.7 Percentage of participants Interval 85.4 to 94.0
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	86.4 Percentage of participants Interval 81.5 to 91.2	89.7 Percentage of participants Interval 85.6 to 93.8	88.9 Percentage of participants Interval 84.4 to 93.3
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	87.6 Percentage of participants Interval 83.0 to 92.2	91.1 Percentage of participants Interval 87.3 to 94.9	88.0 Percentage of participants Interval 83.5 to 92.5
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	84.7 Percentage of participants Interval 79.7 to 89.7	90.2 Percentage of participants Interval 86.2 to 94.1	90.6 Percentage of participants Interval 86.4 to 94.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	85.5 Percentage of participants Interval 80.6 to 90.5	86.3 Percentage of participants Interval 81.7 to 90.9	88.9 Percentage of participants Interval 84.3 to 93.4
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	84.8 Percentage of participants Interval 79.8 to 89.9	87.8 Percentage of participants Interval 83.4 to 92.2	89.3 Percentage of participants Interval 84.9 to 93.7
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	85.3 Percentage of participants Interval 80.4 to 90.3	89.0 Percentage of participants Interval 84.9 to 93.1	91.8 Percentage of participants Interval 87.8 to 95.7

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=293 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Avoiding a Loss of ≥15 Letters	98.9 Percentage of participants Interval 97.6 to 100.0	98.7 Percentage of participants Interval 97.4 to 100.0	98.6 Percentage of participants Interval 97.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Avoiding a Loss of ≥10 Letters	98.1 Percentage of participants Interval 96.5 to 99.7	98.0 Percentage of participants Interval 96.4 to 99.6	98.2 Percentage of participants Interval 96.7 to 99.7
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population Avoiding a Loss of ≥5 Letters	96.7 Percentage of participants Interval 94.5 to 98.8	97.0 Percentage of participants Interval 95.0 to 98.9	95.4 Percentage of participants Interval 93.0 to 97.8

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	98.8 Percentage of participants Interval 97.5 to 100.0	98.9 Percentage of participants Interval 97.7 to 100.0	98.0 Percentage of participants Interval 96.4 to 99.7
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	98.4 Percentage of participants Interval 96.9 to 99.9	98.3 Percentage of participants Interval 96.8 to 99.8	96.9 Percentage of participants Interval 94.8 to 99.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	98.4 Percentage of participants Interval 96.9 to 99.9	98.2 Percentage of participants Interval 96.6 to 99.8	97.6 Percentage of participants Interval 95.8 to 99.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	98.9 Percentage of participants Interval 97.6 to 100.0	98.8 Percentage of participants Interval 97.6 to 100.0	97.6 Percentage of participants Interval 95.8 to 99.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	96.9 Percentage of participants Interval 94.8 to 99.0	98.2 Percentage of participants Interval 96.6 to 99.8	97.6 Percentage of participants Interval 95.7 to 99.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	96.4 Percentage of participants Interval 94.1 to 98.7	98.1 Percentage of participants Interval 96.5 to 99.7	97.5 Percentage of participants Interval 95.6 to 99.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	96.2 Percentage of participants Interval 93.9 to 98.5	99.3 Percentage of participants Interval 98.3 to 100.0	97.3 Percentage of participants Interval 95.3 to 99.3
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	94.9 Percentage of participants Interval 92.2 to 97.6	98.1 Percentage of participants Interval 96.5 to 99.7	97.6 Percentage of participants Interval 95.7 to 99.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	96.0 Percentage of participants Interval 93.6 to 98.4	97.4 Percentage of participants Interval 95.5 to 99.3	97.1 Percentage of participants Interval 95.0 to 99.2
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	95.5 Percentage of participants Interval 92.9 to 98.1	97.8 Percentage of participants Interval 96.0 to 99.5	98.4 Percentage of participants Interval 96.8 to 99.9
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	96.1 Percentage of participants Interval 93.7 to 98.4	96.3 Percentage of participants Interval 94.1 to 98.5	96.1 Percentage of participants Interval 93.7 to 98.5
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	99.4 Percentage of participants Interval 98.5 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	99.7 Percentage of participants Interval 99.1 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	99.7 Percentage of participants Interval 99.1 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	99.7 Percentage of participants Interval 99.0 to 100.0	99.7 Percentage of participants Interval 99.1 to 100.0	99.7 Percentage of participants Interval 99.1 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	100.0 Percentage of participants Interval 100.0 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	99.7 Percentage of participants Interval 99.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	99.6 Percentage of participants Interval 99.0 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	99.3 Percentage of participants Interval 98.4 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	99.7 Percentage of participants Interval 99.0 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0	99.0 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	98.9 Percentage of participants Interval 97.7 to 100.0	98.9 Percentage of participants Interval 97.8 to 100.0	98.5 Percentage of participants Interval 97.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	99.3 Percentage of participants Interval 98.3 to 100.0	99.0 Percentage of participants Interval 97.9 to 100.0	98.9 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	98.9 Percentage of participants Interval 97.6 to 100.0	98.6 Percentage of participants Interval 97.3 to 99.9	99.3 Percentage of participants Interval 98.3 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	99.6 Percentage of participants Interval 98.8 to 100.0	99.0 Percentage of participants Interval 97.8 to 100.0	98.5 Percentage of participants Interval 97.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	99.6 Percentage of participants Interval 98.8 to 100.0	98.3 Percentage of participants Interval 96.8 to 99.8	99.3 Percentage of participants Interval 98.3 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	98.4 Percentage of participants Interval 96.9 to 99.9	98.9 Percentage of participants Interval 97.8 to 100.0	99.6 Percentage of participants Interval 99.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	98.5 Percentage of participants Interval 97.0 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0	98.9 Percentage of participants Interval 97.6 to 100.0

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	99.4 Percentage of participants Interval 98.5 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0	99.4 Percentage of participants Interval 98.5 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	99.0 Percentage of participants Interval 98.0 to 100.0	99.4 Percentage of participants Interval 98.5 to 100.0	99.0 Percentage of participants Interval 98.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	98.7 Percentage of participants Interval 97.5 to 99.9	99.0 Percentage of participants Interval 98.0 to 100.0	99.3 Percentage of participants Interval 98.5 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	99.7 Percentage of participants Interval 99.0 to 100.0	99.7 Percentage of participants Interval 99.0 to 100.0	99.3 Percentage of participants Interval 98.4 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	98.6 Percentage of participants Interval 97.3 to 99.9	99.0 Percentage of participants Interval 97.9 to 100.0	99.0 Percentage of participants Interval 97.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	98.2 Percentage of participants Interval 96.7 to 99.8	99.3 Percentage of participants Interval 98.4 to 100.0	98.7 Percentage of participants Interval 97.4 to 99.9
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	99.7 Percentage of participants Interval 99.0 to 100.0	99.0 Percentage of participants Interval 97.8 to 100.0	99.0 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	98.5 Percentage of participants Interval 97.1 to 99.9	98.6 Percentage of participants Interval 97.3 to 99.9	97.5 Percentage of participants Interval 95.7 to 99.2
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	98.9 Percentage of participants Interval 97.7 to 100.0	98.7 Percentage of participants Interval 97.4 to 99.9	98.2 Percentage of participants Interval 96.7 to 99.8
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	98.1 Percentage of participants Interval 96.5 to 99.7	97.9 Percentage of participants Interval 96.3 to 99.6	98.6 Percentage of participants Interval 97.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	98.5 Percentage of participants Interval 97.0 to 100.0	98.6 Percentage of participants Interval 97.3 to 100.0	98.2 Percentage of participants Interval 96.6 to 99.7
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	98.4 Percentage of participants Interval 96.8 to 99.9	96.5 Percentage of participants Interval 94.5 to 98.6	98.9 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	97.7 Percentage of participants Interval 95.9 to 99.5	98.2 Percentage of participants Interval 96.7 to 99.8	98.6 Percentage of participants Interval 97.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	98.5 Percentage of participants Interval 97.0 to 100.0	98.6 Percentage of participants Interval 97.2 to 99.9	97.0 Percentage of participants Interval 95.0 to 99.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	98.0 Percentage of participants Interval 96.3 to 99.7	97.1 Percentage of participants Interval 95.2 to 99.1	96.5 Percentage of participants Interval 94.3 to 98.7
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	97.7 Percentage of participants Interval 95.9 to 99.5	97.3 Percentage of participants Interval 95.4 to 99.1	96.5 Percentage of participants Interval 94.3 to 98.7
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	96.4 Percentage of participants Interval 94.1 to 98.7	96.3 Percentage of participants Interval 94.1 to 98.5	96.0 Percentage of participants Interval 93.6 to 98.4
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	96.4 Percentage of participants Interval 94.1 to 98.7	98.1 Percentage of participants Interval 96.4 to 99.7	97.2 Percentage of participants Interval 95.2 to 99.2
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	95.7 Percentage of participants Interval 93.2 to 98.1	97.4 Percentage of participants Interval 95.5 to 99.3	96.8 Percentage of participants Interval 94.6 to 99.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	95.2 Percentage of participants Interval 92.5 to 97.8	96.7 Percentage of participants Interval 94.6 to 98.8	95.9 Percentage of participants Interval 93.4 to 98.3
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	94.6 Percentage of participants Interval 91.9 to 97.3	98.5 Percentage of participants Interval 97.1 to 99.9	95.3 Percentage of participants Interval 92.7 to 97.9
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	93.3 Percentage of participants Interval 90.3 to 96.4	97.0 Percentage of participants Interval 95.0 to 99.0	95.1 Percentage of participants Interval 92.4 to 97.7
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	93.6 Percentage of participants Interval 90.6 to 96.6	94.8 Percentage of participants Interval 92.1 to 97.4	95.4 Percentage of participants Interval 92.9 to 98.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	93.4 Percentage of participants Interval 90.3 to 96.5	95.5 Percentage of participants Interval 93.0 to 98.0	95.3 Percentage of participants Interval 92.7 to 98.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	94.8 Percentage of participants Interval 92.2 to 97.5	94.9 Percentage of participants Interval 92.3 to 97.5	94.8 Percentage of participants Interval 92.0 to 97.6

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 4	95.1 Percentage of participants Interval 92.8 to 97.5	97.4 Percentage of participants Interval 95.6 to 99.2	97.7 Percentage of participants Interval 96.1 to 99.4
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 8	96.7 Percentage of participants Interval 94.7 to 98.7	97.1 Percentage of participants Interval 95.3 to 98.9	97.1 Percentage of participants Interval 95.2 to 98.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 12	97.4 Percentage of participants Interval 95.6 to 99.2	96.7 Percentage of participants Interval 94.7 to 98.7	97.0 Percentage of participants Interval 95.1 to 98.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 16	97.7 Percentage of participants Interval 96.0 to 99.4	97.7 Percentage of participants Interval 96.0 to 99.4	96.6 Percentage of participants Interval 94.6 to 98.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 20	96.9 Percentage of participants Interval 95.0 to 98.9	96.7 Percentage of participants Interval 94.7 to 98.7	97.3 Percentage of participants Interval 95.5 to 99.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 24	96.5 Percentage of participants Interval 94.4 to 98.6	96.4 Percentage of participants Interval 94.4 to 98.5	96.4 Percentage of participants Interval 94.3 to 98.4
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 28	96.1 Percentage of participants Interval 93.9 to 98.4	97.3 Percentage of participants Interval 95.5 to 99.1	97.9 Percentage of participants Interval 96.3 to 99.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 32	96.4 Percentage of participants Interval 94.3 to 98.6	96.5 Percentage of participants Interval 94.4 to 98.6	95.0 Percentage of participants Interval 92.5 to 97.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 36	97.5 Percentage of participants Interval 95.7 to 99.3	96.6 Percentage of participants Interval 94.5 to 98.6	97.5 Percentage of participants Interval 95.7 to 99.3
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 40	96.7 Percentage of participants Interval 94.6 to 98.8	95.9 Percentage of participants Interval 93.6 to 98.1	96.7 Percentage of participants Interval 94.7 to 98.8
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 44	96.3 Percentage of participants Interval 94.0 to 98.5	95.8 Percentage of participants Interval 93.5 to 98.1	96.3 Percentage of participants Interval 94.1 to 98.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 48	96.4 Percentage of participants Interval 94.2 to 98.7	95.2 Percentage of participants Interval 92.7 to 97.6	96.1 Percentage of participants Interval 93.8 to 98.3
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 52	96.2 Percentage of participants Interval 93.9 to 98.4	94.7 Percentage of participants Interval 92.1 to 97.3	96.7 Percentage of participants Interval 94.5 to 98.8
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 56	95.6 Percentage of participants Interval 93.1 to 98.0	96.8 Percentage of participants Interval 94.7 to 98.8	96.6 Percentage of participants Interval 94.5 to 98.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 60	95.0 Percentage of participants Interval 92.3 to 97.6	94.6 Percentage of participants Interval 92.0 to 97.2	95.3 Percentage of participants Interval 92.8 to 97.8
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 64	95.9 Percentage of participants Interval 93.5 to 98.2	92.8 Percentage of participants Interval 89.8 to 95.8	93.3 Percentage of participants Interval 90.3 to 96.3
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 68	94.8 Percentage of participants Interval 92.1 to 97.6	93.7 Percentage of participants Interval 90.8 to 96.6	94.9 Percentage of participants Interval 92.1 to 97.6
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 72	94.0 Percentage of participants Interval 91.0 to 96.9	94.6 Percentage of participants Interval 91.9 to 97.4	92.9 Percentage of participants Interval 89.7 to 96.0
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 76	93.7 Percentage of participants Interval 90.8 to 96.7	92.3 Percentage of participants Interval 89.2 to 95.5	94.7 Percentage of participants Interval 92.0 to 97.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 80	92.4 Percentage of participants Interval 89.1 to 95.7	93.8 Percentage of participants Interval 90.9 to 96.6	93.4 Percentage of participants Interval 90.4 to 96.4
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 84	92.7 Percentage of participants Interval 89.6 to 95.8	93.3 Percentage of participants Interval 90.3 to 96.2	92.9 Percentage of participants Interval 89.9 to 96.0
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 88	89.9 Percentage of participants Interval 86.2 to 93.5	91.7 Percentage of participants Interval 88.5 to 95.0	93.4 Percentage of participants Interval 90.4 to 96.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 92	91.7 Percentage of participants Interval 88.3 to 95.1	90.7 Percentage of participants Interval 87.3 to 94.2	92.9 Percentage of participants Interval 89.7 to 96.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 96	90.1 Percentage of participants Interval 86.4 to 93.8	91.1 Percentage of participants Interval 87.7 to 94.5	92.8 Percentage of participants Interval 89.5 to 96.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population Week 100	91.6 Percentage of participants Interval 88.2 to 95.0	90.4 Percentage of participants Interval 87.0 to 93.9	93.6 Percentage of participants Interval 90.5 to 96.7

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: Treatment-Naive Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization. Participants were grouped according to the treatment assigned at randomization. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=208 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=231 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=213 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Avoiding a Loss of ≥15 Letters	98.5 Percentage of participants Interval 96.9 to 100.0	98.7 Percentage of participants Interval 97.2 to 100.0	98.6 Percentage of participants Interval 97.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Avoiding a Loss of ≥10 Letters	98.1 Percentage of participants Interval 96.2 to 99.9	97.8 Percentage of participants Interval 96.0 to 99.7	98.1 Percentage of participants Interval 96.3 to 99.9
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population Avoiding a Loss of ≥5 Letters	97.6 Percentage of participants Interval 95.5 to 99.7	97.4 Percentage of participants Interval 95.4 to 99.4	96.2 Percentage of participants Interval 93.7 to 98.8

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	99.6 Percentage of participants Interval 98.8 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	100.0 Percentage of participants Interval 100.0 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	100.0 Percentage of participants Interval 100.0 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	100.0 Percentage of participants Interval 100.0 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0	99.6 Percentage of participants Interval 98.7 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	100.0 Percentage of participants Interval 100.0 to 100.0	99.2 Percentage of participants Interval 98.0 to 100.0	99.6 Percentage of participants Interval 98.7 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	99.2 Percentage of participants Interval 98.0 to 100.0	99.2 Percentage of participants Interval 98.0 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	99.6 Percentage of participants Interval 98.8 to 100.0	99.6 Percentage of participants Interval 98.7 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	98.6 Percentage of participants Interval 97.1 to 100.0	99.1 Percentage of participants Interval 97.8 to 100.0	99.1 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	99.0 Percentage of participants Interval 97.7 to 100.0	99.2 Percentage of participants Interval 98.1 to 100.0	99.1 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	99.0 Percentage of participants Interval 97.7 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0	99.5 Percentage of participants Interval 98.6 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	99.5 Percentage of participants Interval 98.5 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0	99.1 Percentage of participants Interval 97.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	99.5 Percentage of participants Interval 98.5 to 100.0	98.3 Percentage of participants Interval 96.6 to 99.9	99.5 Percentage of participants Interval 98.6 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	99.0 Percentage of participants Interval 97.6 to 100.0	98.6 Percentage of participants Interval 97.1 to 100.0	100.0 Percentage of participants Interval 100.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	98.1 Percentage of participants Interval 96.2 to 99.9	99.1 Percentage of participants Interval 97.9 to 100.0	98.5 Percentage of participants Interval 96.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	99.0 Percentage of participants Interval 97.7 to 100.0	98.6 Percentage of participants Interval 97.1 to 100.0	98.5 Percentage of participants Interval 96.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	99.0 Percentage of participants Interval 97.7 to 100.0	98.2 Percentage of participants Interval 96.5 to 99.9	97.0 Percentage of participants Interval 94.7 to 99.4
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	99.0 Percentage of participants Interval 97.6 to 100.0	97.7 Percentage of participants Interval 95.7 to 99.7	97.5 Percentage of participants Interval 95.4 to 99.7
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	99.5 Percentage of participants Interval 98.5 to 100.0	98.5 Percentage of participants Interval 96.9 to 100.0	97.5 Percentage of participants Interval 95.3 to 99.7
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	97.5 Percentage of participants Interval 95.3 to 99.7	97.7 Percentage of participants Interval 95.7 to 99.7	97.5 Percentage of participants Interval 95.3 to 99.6
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	96.8 Percentage of participants Interval 94.3 to 99.3	98.1 Percentage of participants Interval 96.3 to 99.9	97.9 Percentage of participants Interval 95.8 to 99.9
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	96.9 Percentage of participants Interval 94.5 to 99.3	99.1 Percentage of participants Interval 97.9 to 100.0	97.0 Percentage of participants Interval 94.7 to 99.4
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	94.9 Percentage of participants Interval 91.8 to 98.0	98.1 Percentage of participants Interval 96.3 to 99.9	97.4 Percentage of participants Interval 95.2 to 99.6
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	96.4 Percentage of participants Interval 93.7 to 99.0	97.2 Percentage of participants Interval 94.9 to 99.4	97.4 Percentage of participants Interval 95.1 to 99.6
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	95.3 Percentage of participants Interval 92.3 to 98.3	97.7 Percentage of participants Interval 95.7 to 99.7	98.5 Percentage of participants Interval 96.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	95.5 Percentage of participants Interval 92.6 to 98.4	96.3 Percentage of participants Interval 93.7 to 98.8	96.7 Percentage of participants Interval 94.1 to 99.3

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	99.6 Percentage of participants Interval 98.8 to 100.0	99.2 Percentage of participants Interval 98.0 to 100.0	99.2 Percentage of participants Interval 98.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	99.2 Percentage of participants Interval 98.0 to 100.0	99.2 Percentage of participants Interval 98.1 to 100.0	98.8 Percentage of participants Interval 97.4 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	99.2 Percentage of participants Interval 98.1 to 100.0	99.2 Percentage of participants Interval 98.1 to 100.0	99.2 Percentage of participants Interval 98.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	99.6 Percentage of participants Interval 98.8 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	98.7 Percentage of participants Interval 97.3 to 100.0	98.8 Percentage of participants Interval 97.3 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	97.8 Percentage of participants Interval 95.9 to 99.7	99.2 Percentage of participants Interval 98.0 to 100.0	99.6 Percentage of participants Interval 98.8 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	99.6 Percentage of participants Interval 98.8 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0	99.1 Percentage of participants Interval 97.9 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	98.2 Percentage of participants Interval 96.4 to 99.9	99.1 Percentage of participants Interval 97.8 to 100.0	98.6 Percentage of participants Interval 97.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	98.6 Percentage of participants Interval 97.0 to 100.0	98.7 Percentage of participants Interval 97.3 to 100.0	98.6 Percentage of participants Interval 97.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	98.5 Percentage of participants Interval 96.9 to 100.0	98.7 Percentage of participants Interval 97.2 to 100.0	98.6 Percentage of participants Interval 97.1 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	98.1 Percentage of participants Interval 96.2 to 99.9	98.7 Percentage of participants Interval 97.2 to 100.0	98.6 Percentage of participants Interval 97.0 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	99.0 Percentage of participants Interval 97.5 to 100.0	96.5 Percentage of participants Interval 94.1 to 98.9	99.5 Percentage of participants Interval 98.6 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	98.5 Percentage of participants Interval 96.9 to 100.0	97.8 Percentage of participants Interval 95.8 to 99.7	99.0 Percentage of participants Interval 97.7 to 100.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	98.1 Percentage of participants Interval 96.2 to 99.9	98.7 Percentage of participants Interval 97.2 to 100.0	96.6 Percentage of participants Interval 94.1 to 99.1
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	98.5 Percentage of participants Interval 96.9 to 100.0	96.4 Percentage of participants Interval 93.9 to 98.8	97.0 Percentage of participants Interval 94.6 to 99.4
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	98.6 Percentage of participants Interval 96.9 to 100.0	96.9 Percentage of participants Interval 94.7 to 99.2	97.0 Percentage of participants Interval 94.7 to 99.4
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	97.0 Percentage of participants Interval 94.6 to 99.4	95.4 Percentage of participants Interval 92.6 to 98.2	95.5 Percentage of participants Interval 92.6 to 98.4
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	97.9 Percentage of participants Interval 95.8 to 99.9	98.1 Percentage of participants Interval 96.2 to 99.9	97.5 Percentage of participants Interval 95.3 to 99.7
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	96.0 Percentage of participants Interval 93.2 to 98.7	97.2 Percentage of participants Interval 95.0 to 99.4	96.4 Percentage of participants Interval 93.8 to 99.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	95.8 Percentage of participants Interval 92.9 to 98.6	96.3 Percentage of participants Interval 93.7 to 98.8	96.3 Percentage of participants Interval 93.6 to 99.0
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	95.9 Percentage of participants Interval 93.1 to 98.7	98.6 Percentage of participants Interval 97.1 to 100.0	95.5 Percentage of participants Interval 92.6 to 98.4
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	93.9 Percentage of participants Interval 90.5 to 97.2	96.7 Percentage of participants Interval 94.4 to 99.1	95.3 Percentage of participants Interval 92.3 to 98.3
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	93.8 Percentage of participants Interval 90.4 to 97.2	94.8 Percentage of participants Interval 91.8 to 97.8	95.8 Percentage of participants Interval 93.0 to 98.6
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	92.7 Percentage of participants Interval 89.0 to 96.4	96.2 Percentage of participants Interval 93.6 to 98.8	95.7 Percentage of participants Interval 92.9 to 98.6
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	94.5 Percentage of participants Interval 91.3 to 97.6	94.5 Percentage of participants Interval 91.4 to 97.5	96.1 Percentage of participants Interval 93.3 to 98.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 4	95.5 Percentage of participants Interval 92.9 to 98.1	97.1 Percentage of participants Interval 95.0 to 99.2	97.5 Percentage of participants Interval 95.6 to 99.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 8	96.3 Percentage of participants Interval 93.9 to 98.6	97.1 Percentage of participants Interval 95.1 to 99.2	96.3 Percentage of participants Interval 93.9 to 98.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 12	97.5 Percentage of participants Interval 95.6 to 99.5	97.1 Percentage of participants Interval 95.0 to 99.2	97.0 Percentage of participants Interval 94.9 to 99.2
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 16	97.1 Percentage of participants Interval 95.0 to 99.2	98.3 Percentage of participants Interval 96.7 to 99.9	97.0 Percentage of participants Interval 94.7 to 99.2
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 20	96.6 Percentage of participants Interval 94.3 to 98.9	96.2 Percentage of participants Interval 93.8 to 98.6	97.8 Percentage of participants Interval 96.0 to 99.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 24	96.1 Percentage of participants Interval 93.6 to 98.6	97.1 Percentage of participants Interval 95.1 to 99.2	97.4 Percentage of participants Interval 95.4 to 99.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 28	96.8 Percentage of participants Interval 94.5 to 99.1	97.8 Percentage of participants Interval 96.0 to 99.7	98.2 Percentage of participants Interval 96.4 to 99.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 32	96.8 Percentage of participants Interval 94.5 to 99.1	96.4 Percentage of participants Interval 93.9 to 98.8	95.8 Percentage of participants Interval 93.1 to 98.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 36	97.2 Percentage of participants Interval 95.0 to 99.4	96.5 Percentage of participants Interval 94.1 to 98.9	98.1 Percentage of participants Interval 96.3 to 99.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 40	96.7 Percentage of participants Interval 94.3 to 99.1	96.9 Percentage of participants Interval 94.7 to 99.1	97.2 Percentage of participants Interval 95.0 to 99.4
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 44	96.2 Percentage of participants Interval 93.6 to 98.8	96.0 Percentage of participants Interval 93.4 to 98.5	97.7 Percentage of participants Interval 95.6 to 99.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 48	96.4 Percentage of participants Interval 93.9 to 99.0	95.6 Percentage of participants Interval 93.0 to 98.3	96.2 Percentage of participants Interval 93.7 to 98.8
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 52	97.5 Percentage of participants Interval 95.4 to 99.7	94.6 Percentage of participants Interval 91.7 to 97.6	98.0 Percentage of participants Interval 96.2 to 99.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 56	96.7 Percentage of participants Interval 94.2 to 99.1	97.8 Percentage of participants Interval 95.8 to 99.7	96.6 Percentage of participants Interval 94.1 to 99.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 60	95.7 Percentage of participants Interval 92.9 to 98.4	94.1 Percentage of participants Interval 91.1 to 97.2	95.5 Percentage of participants Interval 92.6 to 98.4
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 64	96.2 Percentage of participants Interval 93.7 to 98.8	92.1 Percentage of participants Interval 88.6 to 95.6	94.1 Percentage of participants Interval 90.8 to 97.3
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 68	95.0 Percentage of participants Interval 92.0 to 98.0	93.0 Percentage of participants Interval 89.6 to 96.4	94.0 Percentage of participants Interval 90.7 to 97.3
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 72	94.8 Percentage of participants Interval 91.7 to 97.9	94.2 Percentage of participants Interval 90.9 to 97.4	92.4 Percentage of participants Interval 88.7 to 96.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 76	94.0 Percentage of participants Interval 90.7 to 97.3	93.2 Percentage of participants Interval 89.9 to 96.5	93.8 Percentage of participants Interval 90.4 to 97.2
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 80	92.7 Percentage of participants Interval 89.0 to 96.4	94.5 Percentage of participants Interval 91.4 to 97.5	94.1 Percentage of participants Interval 90.8 to 97.5
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 84	93.8 Percentage of participants Interval 90.4 to 97.2	93.9 Percentage of participants Interval 90.7 to 97.1	93.5 Percentage of participants Interval 90.0 to 96.9
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 88	90.8 Percentage of participants Interval 86.7 to 94.8	92.1 Percentage of participants Interval 88.5 to 95.7	93.7 Percentage of participants Interval 90.2 to 97.1
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 92	91.3 Percentage of participants Interval 87.4 to 95.3	90.6 Percentage of participants Interval 86.7 to 94.5	93.1 Percentage of participants Interval 89.4 to 96.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 96	88.5 Percentage of participants Interval 84.0 to 93.0	92.0 Percentage of participants Interval 88.4 to 95.7	93.0 Percentage of participants Interval 89.4 to 96.7
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population Week 100	90.4 Percentage of participants Interval 86.3 to 94.5	91.7 Percentage of participants Interval 88.1 to 95.4	94.5 Percentage of participants Interval 91.2 to 97.8

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: ITT Population and Treatment-Naive Population. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=294 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	38.3 Percentage of participants Interval 32.6 to 44.0	32.4 Percentage of participants Interval 27.2 to 37.6	33.5 Percentage of participants Interval 28.1 to 38.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	38.1 Percentage of participants Interval 31.7 to 44.5	34.4 Percentage of participants Interval 28.5 to 40.4	35.5 Percentage of participants Interval 29.2 to 41.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 92	45.6 Percentage of participants Interval 39.7 to 51.6	38.3 Percentage of participants Interval 32.7 to 43.9	45.0 Percentage of participants Interval 38.9 to 51.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 4	14.7 Percentage of participants Interval 11.0 to 18.5	13.0 Percentage of participants Interval 9.4 to 16.7	13.2 Percentage of participants Interval 9.5 to 16.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 8	17.3 Percentage of participants Interval 13.1 to 21.5	20.4 Percentage of participants Interval 16.0 to 24.8	18.1 Percentage of participants Interval 13.8 to 22.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 12	23.2 Percentage of participants Interval 18.5 to 27.8	25.5 Percentage of participants Interval 20.8 to 30.3	22.7 Percentage of participants Interval 18.1 to 27.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 16	27.3 Percentage of participants Interval 22.4 to 32.2	28.0 Percentage of participants Interval 23.2 to 32.8	25.8 Percentage of participants Interval 21.0 to 30.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 20	28.7 Percentage of participants Interval 23.7 to 33.8	24.0 Percentage of participants Interval 19.3 to 28.8	26.5 Percentage of participants Interval 21.7 to 31.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 24	33.3 Percentage of participants Interval 28.0 to 38.6	29.1 Percentage of participants Interval 24.0 to 34.1	27.6 Percentage of participants Interval 22.6 to 32.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 28	34.9 Percentage of participants Interval 29.4 to 40.3	30.7 Percentage of participants Interval 25.6 to 35.8	28.8 Percentage of participants Interval 23.6 to 34.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 32	39.0 Percentage of participants Interval 33.5 to 44.6	30.4 Percentage of participants Interval 25.2 to 35.7	27.5 Percentage of participants Interval 22.4 to 32.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 36	36.3 Percentage of participants Interval 30.9 to 41.8	35.8 Percentage of participants Interval 30.4 to 41.2	33.2 Percentage of participants Interval 27.9 to 38.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 40	41.0 Percentage of participants Interval 35.3 to 46.6	34.2 Percentage of participants Interval 28.9 to 39.5	34.5 Percentage of participants Interval 29.0 to 40.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 44	40.6 Percentage of participants Interval 35.0 to 46.3	33.5 Percentage of participants Interval 28.1 to 38.8	38.5 Percentage of participants Interval 32.9 to 44.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 48	36.6 Percentage of participants Interval 30.8 to 42.4	32.6 Percentage of participants Interval 27.4 to 37.8	33.9 Percentage of participants Interval 28.4 to 39.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 52	39.3 Percentage of participants Interval 33.7 to 45.0	34.7 Percentage of participants Interval 29.3 to 40.2	38.4 Percentage of participants Interval 32.7 to 44.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 56	43.4 Percentage of participants Interval 37.7 to 49.2	33.2 Percentage of participants Interval 27.9 to 38.5	40.3 Percentage of participants Interval 34.4 to 46.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 60	41.2 Percentage of participants Interval 35.3 to 47.0	34.2 Percentage of participants Interval 28.8 to 39.6	39.0 Percentage of participants Interval 33.2 to 44.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 64	44.4 Percentage of participants Interval 38.5 to 50.2	31.6 Percentage of participants Interval 26.4 to 36.8	35.0 Percentage of participants Interval 29.4 to 40.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 68	40.2 Percentage of participants Interval 34.4 to 46.0	33.5 Percentage of participants Interval 27.9 to 39.0	39.0 Percentage of participants Interval 33.2 to 44.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 72	41.0 Percentage of participants Interval 35.0 to 47.1	34.4 Percentage of participants Interval 28.8 to 39.9	36.1 Percentage of participants Interval 30.4 to 41.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 76	39.7 Percentage of participants Interval 34.0 to 45.5	35.7 Percentage of participants Interval 30.2 to 41.3	39.1 Percentage of participants Interval 33.2 to 44.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 80	43.4 Percentage of participants Interval 37.4 to 49.4	32.8 Percentage of participants Interval 27.4 to 38.2	38.7 Percentage of participants Interval 32.7 to 44.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 84	41.7 Percentage of participants Interval 35.9 to 47.5	33.8 Percentage of participants Interval 28.2 to 39.4	40.5 Percentage of participants Interval 34.7 to 46.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 88	42.6 Percentage of participants Interval 36.8 to 48.4	32.5 Percentage of participants Interval 27.0 to 38.0	41.7 Percentage of participants Interval 35.7 to 47.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 96	46.0 Percentage of participants Interval 39.9 to 52.1	37.2 Percentage of participants Interval 31.7 to 42.7	40.6 Percentage of participants Interval 34.5 to 46.7
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population Week 100	44.5 Percentage of participants Interval 38.4 to 50.5	34.3 Percentage of participants Interval 28.8 to 39.7	44.3 Percentage of participants Interval 38.1 to 50.5

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 4	15.1 Percentage of participants Interval 10.8 to 19.3	13.5 Percentage of participants Interval 9.4 to 17.6	12.8 Percentage of participants Interval 8.6 to 17.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 8	17.0 Percentage of participants Interval 12.4 to 21.7	22.2 Percentage of participants Interval 17.0 to 27.3	17.7 Percentage of participants Interval 13.0 to 22.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 12	22.6 Percentage of participants Interval 17.4 to 27.8	26.3 Percentage of participants Interval 21.0 to 31.6	22.7 Percentage of participants Interval 17.6 to 27.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 16	26.1 Percentage of participants Interval 20.6 to 31.5	30.0 Percentage of participants Interval 24.4 to 35.5	26.1 Percentage of participants Interval 20.6 to 31.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 20	28.4 Percentage of participants Interval 22.7 to 34.1	26.2 Percentage of participants Interval 20.7 to 31.7	25.9 Percentage of participants Interval 20.5 to 31.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 24	34.2 Percentage of participants Interval 28.2 to 40.3	30.5 Percentage of participants Interval 24.8 to 36.3	27.3 Percentage of participants Interval 21.7 to 32.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 28	35.4 Percentage of participants Interval 29.1 to 41.6	32.9 Percentage of participants Interval 27.0 to 38.9	29.6 Percentage of participants Interval 23.7 to 35.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 32	38.4 Percentage of participants Interval 32.0 to 44.7	31.5 Percentage of participants Interval 25.5 to 37.5	28.9 Percentage of participants Interval 23.0 to 34.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 36	37.0 Percentage of participants Interval 30.7 to 43.3	38.0 Percentage of participants Interval 31.9 to 44.2	34.6 Percentage of participants Interval 28.5 to 40.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 40	41.4 Percentage of participants Interval 34.9 to 47.8	36.4 Percentage of participants Interval 30.2 to 42.5	34.6 Percentage of participants Interval 28.3 to 40.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 44	40.3 Percentage of participants Interval 33.8 to 46.7	34.3 Percentage of participants Interval 28.2 to 40.4	40.7 Percentage of participants Interval 34.2 to 47.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 48	36.7 Percentage of participants Interval 30.1 to 43.4	34.9 Percentage of participants Interval 28.9 to 40.9	36.5 Percentage of participants Interval 30.1 to 42.9
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 52	39.1 Percentage of participants Interval 32.6 to 45.6	37.0 Percentage of participants Interval 30.8 to 43.2	39.8 Percentage of participants Interval 33.2 to 46.4
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 56	44.7 Percentage of participants Interval 38.1 to 51.2	35.2 Percentage of participants Interval 29.1 to 41.3	41.7 Percentage of participants Interval 35.0 to 48.5
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 60	40.9 Percentage of participants Interval 34.3 to 47.5	36.9 Percentage of participants Interval 30.6 to 43.2	39.2 Percentage of participants Interval 32.7 to 45.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 64	44.0 Percentage of participants Interval 37.4 to 50.6	33.6 Percentage of participants Interval 27.5 to 39.7	35.4 Percentage of participants Interval 29.0 to 41.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 68	39.7 Percentage of participants Interval 33.2 to 46.2	35.5 Percentage of participants Interval 29.1 to 41.9	40.0 Percentage of participants Interval 33.4 to 46.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 72	40.0 Percentage of participants Interval 33.1 to 46.8	37.7 Percentage of participants Interval 31.2 to 44.2	38.3 Percentage of participants Interval 31.7 to 45.0
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 76	40.6 Percentage of participants Interval 34.0 to 47.2	37.8 Percentage of participants Interval 31.4 to 44.2	39.1 Percentage of participants Interval 32.4 to 45.8
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 80	44.9 Percentage of participants Interval 38.0 to 51.8	37.3 Percentage of participants Interval 30.9 to 43.7	40.9 Percentage of participants Interval 34.1 to 47.6
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 84	43.1 Percentage of participants Interval 36.5 to 49.8	36.0 Percentage of participants Interval 29.6 to 42.4	41.4 Percentage of participants Interval 34.8 to 48.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 88	42.3 Percentage of participants Interval 35.6 to 49.1	33.5 Percentage of participants Interval 27.2 to 39.8	41.5 Percentage of participants Interval 34.7 to 48.2
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 92	47.1 Percentage of participants Interval 40.2 to 54.0	42.6 Percentage of participants Interval 36.1 to 49.2	45.2 Percentage of participants Interval 38.2 to 52.1
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 96	44.6 Percentage of participants Interval 37.7 to 51.5	39.5 Percentage of participants Interval 33.1 to 45.8	41.4 Percentage of participants Interval 34.4 to 48.3
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 100	45.6 Percentage of participants Interval 38.7 to 52.5	36.9 Percentage of participants Interval 30.6 to 43.2	44.9 Percentage of participants Interval 37.8 to 52.0

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: ITT Population and Treatment-Naive Population. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. <69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=293 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	73.2 Percentage of participants Interval 68.2 to 78.3	71.6 Percentage of participants Interval 66.7 to 76.4	68.5 Percentage of participants Interval 63.6 to 73.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	73.6 Percentage of participants Interval 68.0 to 79.3	74.2 Percentage of participants Interval 68.9 to 79.5	72.1 Percentage of participants Interval 66.6 to 77.7

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. <69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 4	56.7 Percentage of participants Interval 51.6 to 61.7	57.8 Percentage of participants Interval 53.2 to 62.4	54.4 Percentage of participants Interval 49.7 to 59.1
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 8	61.3 Percentage of participants Interval 56.4 to 66.2	65.7 Percentage of participants Interval 61.1 to 70.3	59.4 Percentage of participants Interval 54.7 to 64.1
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 12	68.0 Percentage of participants Interval 63.2 to 72.8	67.8 Percentage of participants Interval 63.2 to 72.4	65.2 Percentage of participants Interval 60.4 to 70.0
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 16	66.8 Percentage of participants Interval 61.9 to 71.7	69.2 Percentage of participants Interval 64.6 to 73.7	64.6 Percentage of participants Interval 59.7 to 69.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 20	69.6 Percentage of participants Interval 64.8 to 74.5	67.3 Percentage of participants Interval 62.5 to 72.0	66.0 Percentage of participants Interval 61.2 to 70.7
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 24	70.6 Percentage of participants Interval 65.7 to 75.6	69.1 Percentage of participants Interval 64.4 to 73.8	65.5 Percentage of participants Interval 60.6 to 70.4
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 28	72.0 Percentage of participants Interval 67.1 to 76.9	69.9 Percentage of participants Interval 65.2 to 74.5	67.0 Percentage of participants Interval 62.2 to 71.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 32	72.6 Percentage of participants Interval 67.6 to 77.7	71.9 Percentage of participants Interval 67.1 to 76.7	67.3 Percentage of participants Interval 62.4 to 72.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 36	71.4 Percentage of participants Interval 66.3 to 76.4	69.6 Percentage of participants Interval 64.6 to 74.5	70.1 Percentage of participants Interval 65.2 to 75.1
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 40	73.8 Percentage of participants Interval 68.9 to 78.6	70.8 Percentage of participants Interval 65.9 to 75.6	70.4 Percentage of participants Interval 65.4 to 75.4
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 44	73.7 Percentage of participants Interval 68.7 to 78.8	71.1 Percentage of participants Interval 66.3 to 75.9	69.0 Percentage of participants Interval 64.0 to 73.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 48	73.1 Percentage of participants Interval 67.8 to 78.3	73.0 Percentage of participants Interval 68.1 to 77.9	67.1 Percentage of participants Interval 62.1 to 72.0
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 52	74.5 Percentage of participants Interval 69.5 to 79.5	69.8 Percentage of participants Interval 64.8 to 74.8	71.0 Percentage of participants Interval 66.1 to 75.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 56	74.7 Percentage of participants Interval 69.7 to 79.8	73.4 Percentage of participants Interval 68.6 to 78.2	71.9 Percentage of participants Interval 66.8 to 76.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 60	70.3 Percentage of participants Interval 64.9 to 75.7	67.1 Percentage of participants Interval 62.0 to 72.3	69.4 Percentage of participants Interval 64.3 to 74.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 64	74.5 Percentage of participants Interval 69.5 to 79.6	68.1 Percentage of participants Interval 63.0 to 73.2	68.2 Percentage of participants Interval 63.0 to 73.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 68	71.9 Percentage of participants Interval 66.6 to 77.2	68.4 Percentage of participants Interval 63.2 to 73.6	72.3 Percentage of participants Interval 67.2 to 77.4
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 72	68.8 Percentage of participants Interval 63.2 to 74.3	72.2 Percentage of participants Interval 67.2 to 77.3	66.2 Percentage of participants Interval 60.8 to 71.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 76	70.1 Percentage of participants Interval 64.8 to 75.5	69.0 Percentage of participants Interval 63.9 to 74.2	70.7 Percentage of participants Interval 65.3 to 76.1
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 80	72.4 Percentage of participants Interval 67.0 to 77.8	70.9 Percentage of participants Interval 65.8 to 76.0	69.5 Percentage of participants Interval 64.0 to 74.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 84	72.7 Percentage of participants Interval 67.4 to 78.0	71.6 Percentage of participants Interval 66.5 to 76.8	71.4 Percentage of participants Interval 66.0 to 76.7
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 88	68.7 Percentage of participants Interval 63.3 to 74.2	70.3 Percentage of participants Interval 65.1 to 75.5	71.3 Percentage of participants Interval 65.9 to 76.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 92	71.6 Percentage of participants Interval 66.1 to 77.0	73.5 Percentage of participants Interval 68.4 to 78.6	69.5 Percentage of participants Interval 64.0 to 74.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 96	74.9 Percentage of participants Interval 69.5 to 80.3	73.1 Percentage of participants Interval 68.0 to 78.2	73.2 Percentage of participants Interval 67.9 to 78.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population Week 100	73.5 Percentage of participants Interval 68.1 to 78.9	70.0 Percentage of participants Interval 64.8 to 75.1	76.4 Percentage of participants Interval 71.2 to 81.6

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. <69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 4	57.5 Percentage of participants Interval 51.9 to 63.1	59.9 Percentage of participants Interval 54.8 to 64.9	56.0 Percentage of participants Interval 50.7 to 61.4
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 8	62.3 Percentage of participants Interval 56.8 to 67.7	67.0 Percentage of participants Interval 61.9 to 72.1	59.9 Percentage of participants Interval 54.5 to 65.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 12	68.9 Percentage of participants Interval 63.6 to 74.1	70.2 Percentage of participants Interval 65.1 to 75.3	67.5 Percentage of participants Interval 62.1 to 73.0
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 16	66.8 Percentage of participants Interval 61.3 to 72.3	70.7 Percentage of participants Interval 65.7 to 75.7	65.0 Percentage of participants Interval 59.4 to 70.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 20	70.2 Percentage of participants Interval 64.7 to 75.6	69.2 Percentage of participants Interval 64.0 to 74.3	67.4 Percentage of participants Interval 62.1 to 72.8
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 24	71.1 Percentage of participants Interval 65.6 to 76.5	71.7 Percentage of participants Interval 66.6 to 76.8	66.2 Percentage of participants Interval 60.8 to 71.7
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 28	73.5 Percentage of participants Interval 68.1 to 79.0	71.0 Percentage of participants Interval 65.9 to 76.1	69.4 Percentage of participants Interval 64.0 to 74.8
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 32	74.3 Percentage of participants Interval 68.7 to 80.0	74.8 Percentage of participants Interval 69.4 to 80.1	70.2 Percentage of participants Interval 64.6 to 75.8
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 36	71.8 Percentage of participants Interval 66.0 to 77.5	71.2 Percentage of participants Interval 65.6 to 76.8	72.4 Percentage of participants Interval 66.9 to 77.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 40	74.0 Percentage of participants Interval 68.6 to 79.5	73.7 Percentage of participants Interval 68.4 to 79.0	72.3 Percentage of participants Interval 66.7 to 77.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 44	73.8 Percentage of participants Interval 68.1 to 79.4	74.3 Percentage of participants Interval 69.1 to 79.6	73.5 Percentage of participants Interval 68.0 to 78.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 48	73.1 Percentage of participants Interval 67.3 to 79.0	76.2 Percentage of participants Interval 70.9 to 81.5	70.5 Percentage of participants Interval 65.0 to 75.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 52	73.9 Percentage of participants Interval 68.2 to 79.5	73.3 Percentage of participants Interval 67.7 to 78.8	75.5 Percentage of participants Interval 70.1 to 80.9
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 56	75.9 Percentage of participants Interval 70.3 to 81.5	75.5 Percentage of participants Interval 70.3 to 80.7	74.7 Percentage of participants Interval 69.1 to 80.3
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 60	69.9 Percentage of participants Interval 63.9 to 76.0	70.9 Percentage of participants Interval 65.2 to 76.7	71.5 Percentage of participants Interval 65.8 to 77.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 64	73.7 Percentage of participants Interval 67.9 to 79.4	70.6 Percentage of participants Interval 65.0 to 76.2	70.4 Percentage of participants Interval 64.5 to 76.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 68	71.8 Percentage of participants Interval 65.8 to 77.7	68.4 Percentage of participants Interval 62.5 to 74.3	73.9 Percentage of participants Interval 68.2 to 79.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 72	67.0 Percentage of participants Interval 60.6 to 73.3	73.9 Percentage of participants Interval 68.2 to 79.6	68.6 Percentage of participants Interval 62.6 to 74.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 76	70.3 Percentage of participants Interval 64.1 to 76.4	72.1 Percentage of participants Interval 66.4 to 77.8	71.7 Percentage of participants Interval 65.7 to 77.8
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 80	73.2 Percentage of participants Interval 67.0 to 79.3	72.5 Percentage of participants Interval 66.8 to 78.3	72.6 Percentage of participants Interval 66.6 to 78.6
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 84	73.4 Percentage of participants Interval 67.4 to 79.4	72.2 Percentage of participants Interval 66.4 to 78.0	72.5 Percentage of participants Interval 66.6 to 78.5
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 88	68.1 Percentage of participants Interval 62.0 to 74.3	70.4 Percentage of participants Interval 64.5 to 76.2	75.3 Percentage of participants Interval 69.3 to 81.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 92	70.5 Percentage of participants Interval 64.2 to 76.8	74.5 Percentage of participants Interval 68.6 to 80.4	73.2 Percentage of participants Interval 67.2 to 79.2
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 96	72.7 Percentage of participants Interval 66.4 to 79.0	74.8 Percentage of participants Interval 69.1 to 80.5	73.8 Percentage of participants Interval 67.9 to 79.8
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 100	71.2 Percentage of participants Interval 64.9 to 77.4	70.7 Percentage of participants Interval 64.8 to 76.6	77.7 Percentage of participants Interval 71.9 to 83.5

SECONDARY outcome

Timeframe: Baseline, average of Weeks 48, 52, and 56

Population: ITT Population and Treatment-Naive Population. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=294 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	0.8 Percentage of participants Interval 0.0 to 1.8	0.0 Percentage of participants Interval 0.0 to 0.0	0.7 Percentage of participants Interval 0.0 to 1.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	1.0 Percentage of participants Interval 0.0 to 2.3	0.0 Percentage of participants Interval 0.0 to 0.0	0.5 Percentage of participants Interval 0.0 to 1.4

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 4	1.6 Percentage of participants Interval 0.2 to 3.0	1.7 Percentage of participants Interval 0.2 to 3.1	0.3 Percentage of participants Interval 0.0 to 1.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 8	1.3 Percentage of participants Interval 0.0 to 2.6	0.6 Percentage of participants Interval 0.0 to 1.5	0.3 Percentage of participants Interval 0.0 to 1.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 12	1.3 Percentage of participants Interval 0.1 to 2.6	0.7 Percentage of participants Interval 0.0 to 1.6	0.6 Percentage of participants Interval 0.0 to 1.5
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 16	0.3 Percentage of participants Interval 0.0 to 1.0	0.3 Percentage of participants Interval 0.0 to 0.9	0.7 Percentage of participants Interval 0.0 to 1.5
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 20	1.0 Percentage of participants Interval 0.0 to 2.2	0.3 Percentage of participants Interval 0.0 to 0.9	1.0 Percentage of participants Interval 0.0 to 2.1
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 24	0.7 Percentage of participants Interval 0.0 to 1.7	0.3 Percentage of participants Interval 0.0 to 1.0	1.3 Percentage of participants Interval 0.1 to 2.6
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 28	1.1 Percentage of participants Interval 0.0 to 2.2	0.3 Percentage of participants Interval 0.0 to 1.0	0.7 Percentage of participants Interval 0.0 to 1.6
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 32	0.7 Percentage of participants Interval 0.0 to 1.7	1.4 Percentage of participants Interval 0.1 to 2.8	1.1 Percentage of participants Interval 0.0 to 2.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 36	0.7 Percentage of participants Interval 0.0 to 1.7	1.3 Percentage of participants Interval 0.1 to 2.6	0.4 Percentage of participants Interval 0.0 to 1.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 40	1.1 Percentage of participants Interval 0.0 to 2.4	1.4 Percentage of participants Interval 0.1 to 2.7	1.1 Percentage of participants Interval 0.0 to 2.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 44	0.4 Percentage of participants Interval 0.0 to 1.1	1.0 Percentage of participants Interval 0.0 to 2.2	1.1 Percentage of participants Interval 0.0 to 2.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 48	0.8 Percentage of participants Interval 0.0 to 1.9	0.7 Percentage of participants Interval 0.0 to 1.6	1.4 Percentage of participants Interval 0.1 to 2.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 52	0.4 Percentage of participants Interval 0.0 to 1.2	0.4 Percentage of participants Interval 0.0 to 1.1	1.1 Percentage of participants Interval 0.0 to 2.2
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 56	1.1 Percentage of participants Interval 0.0 to 2.4	1.0 Percentage of participants Interval 0.0 to 2.2	0.8 Percentage of participants Interval 0.0 to 1.8
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 60	1.2 Percentage of participants Interval 0.0 to 2.5	0.7 Percentage of participants Interval 0.0 to 1.7	1.5 Percentage of participants Interval 0.1 to 2.9
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 64	1.2 Percentage of participants Interval 0.0 to 2.4	0.7 Percentage of participants Interval 0.0 to 1.6	2.0 Percentage of participants Interval 0.3 to 3.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 68	1.2 Percentage of participants Interval 0.0 to 2.5	1.1 Percentage of participants Interval 0.0 to 2.4	0.4 Percentage of participants Interval 0.0 to 1.1
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 72	1.2 Percentage of participants Interval 0.0 to 2.5	1.9 Percentage of participants Interval 0.3 to 3.6	1.5 Percentage of participants Interval 0.1 to 3.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 76	2.7 Percentage of participants Interval 0.8 to 4.7	1.8 Percentage of participants Interval 0.2 to 3.4	2.0 Percentage of participants Interval 0.3 to 3.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 80	2.4 Percentage of participants Interval 0.6 to 4.3	2.6 Percentage of participants Interval 0.7 to 4.6	1.6 Percentage of participants Interval 0.1 to 3.1
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 84	2.7 Percentage of participants Interval 0.7 to 4.6	1.2 Percentage of participants Interval 0.0 to 2.5	1.9 Percentage of participants Interval 0.3 to 3.5
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 88	2.3 Percentage of participants Interval 0.5 to 4.1	1.9 Percentage of participants Interval 0.3 to 3.4	1.2 Percentage of participants Interval 0.0 to 2.5
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 92	3.2 Percentage of participants Interval 1.0 to 5.4	0.8 Percentage of participants Interval 0.0 to 1.8	1.6 Percentage of participants Interval 0.1 to 3.1
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 96	2.9 Percentage of participants Interval 0.8 to 5.0	2.3 Percentage of participants Interval 0.5 to 4.1	2.0 Percentage of participants Interval 0.3 to 3.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population Week 100	2.7 Percentage of participants Interval 0.7 to 4.7	3.3 Percentage of participants Interval 1.2 to 5.5	2.5 Percentage of participants Interval 0.5 to 4.4

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 32	0.9 Percentage of participants Interval 0.0 to 2.2	1.4 Percentage of participants Interval 0.0 to 2.9	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 36	1.0 Percentage of participants Interval 0.0 to 2.3	1.7 Percentage of participants Interval 0.1 to 3.4	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 40	1.0 Percentage of participants Interval 0.0 to 2.2	1.8 Percentage of participants Interval 0.1 to 3.5	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 4	2.0 Percentage of participants Interval 0.3 to 3.8	1.7 Percentage of participants Interval 0.1 to 3.2	0.4 Percentage of participants Interval 0.0 to 1.2
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 8	1.6 Percentage of participants Interval 0.1 to 3.2	0.8 Percentage of participants Interval 0.0 to 1.9	0.4 Percentage of participants Interval 0.0 to 1.2
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 12	1.2 Percentage of participants Interval 0.0 to 2.6	0.4 Percentage of participants Interval 0.0 to 1.2	0.8 Percentage of participants Interval 0.0 to 2.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 16	0.4 Percentage of participants Interval 0.0 to 1.2	0.4 Percentage of participants Interval 0.0 to 1.2	0.9 Percentage of participants Interval 0.0 to 2.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 20	0.9 Percentage of participants Interval 0.0 to 2.1	0.4 Percentage of participants Interval 0.0 to 1.2	0.9 Percentage of participants Interval 0.0 to 2.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 24	0.9 Percentage of participants Interval 0.0 to 2.1	0.4 Percentage of participants Interval 0.0 to 1.2	0.8 Percentage of participants Interval 0.0 to 2.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 28	1.3 Percentage of participants Interval 0.0 to 2.8	0.4 Percentage of participants Interval 0.0 to 1.3	0.4 Percentage of participants Interval 0.0 to 1.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 44	0.5 Percentage of participants Interval 0.0 to 1.4	1.3 Percentage of participants Interval 0.0 to 2.8	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 48	1.0 Percentage of participants Interval 0.0 to 2.4	0.9 Percentage of participants Interval 0.0 to 2.1	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 52	0.0 Percentage of participants Interval 0.0 to 0.0	0.5 Percentage of participants Interval 0.0 to 1.4	0.0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 56	1.4 Percentage of participants Interval 0.0 to 3.0	0.9 Percentage of participants Interval 0.0 to 2.0	1.0 Percentage of participants Interval 0.0 to 2.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 60	0.9 Percentage of participants Interval 0.0 to 2.2	0.9 Percentage of participants Interval 0.0 to 2.2	1.0 Percentage of participants Interval 0.0 to 2.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 64	0.5 Percentage of participants Interval 0.0 to 1.4	0.9 Percentage of participants Interval 0.0 to 2.0	2.0 Percentage of participants Interval 0.1 to 4.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 68	0.5 Percentage of participants Interval 0.0 to 1.5	1.4 Percentage of participants Interval 0.0 to 3.0	0.5 Percentage of participants Interval 0.0 to 1.4
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 72	1.0 Percentage of participants Interval 0.0 to 2.4	1.4 Percentage of participants Interval 0.0 to 3.1	2.0 Percentage of participants Interval 0.1 to 3.9
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 76	2.0 Percentage of participants Interval 0.1 to 3.9	1.8 Percentage of participants Interval 0.1 to 3.6	2.6 Percentage of participants Interval 0.4 to 4.7
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 80	1.6 Percentage of participants Interval 0.0 to 3.4	2.9 Percentage of participants Interval 0.6 to 5.2	1.5 Percentage of participants Interval 0.0 to 3.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 84	2.1 Percentage of participants Interval 0.1 to 4.1	1.0 Percentage of participants Interval 0.0 to 2.3	2.0 Percentage of participants Interval 0.1 to 3.9
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 88	1.5 Percentage of participants Interval 0.0 to 3.2	1.9 Percentage of participants Interval 0.1 to 3.7	1.6 Percentage of participants Interval 0.0 to 3.3
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 92	3.2 Percentage of participants Interval 0.7 to 5.6	0.5 Percentage of participants Interval 0.0 to 1.5	2.1 Percentage of participants Interval 0.1 to 4.1
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 96	2.7 Percentage of participants Interval 0.4 to 5.0	2.4 Percentage of participants Interval 0.3 to 4.5	2.0 Percentage of participants Interval 0.1 to 4.0
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population Week 100	3.0 Percentage of participants Interval 0.6 to 5.4	3.8 Percentage of participants Interval 1.2 to 6.3	2.1 Percentage of participants Interval 0.1 to 4.1

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with non-missing, valid assessments at Baseline and each timepoint were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 16	34.5 Percentage of participants Interval 29.1 to 39.8	38.0 Percentage of participants Interval 32.5 to 43.6	34.0 Percentage of participants Interval 28.6 to 39.5
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 52	43.4 Percentage of participants Interval 37.4 to 49.4	43.9 Percentage of participants Interval 37.9 to 49.8	46.2 Percentage of participants Interval 40.2 to 52.2
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 96	53.5 Percentage of participants Interval 46.9 to 60.1	44.3 Percentage of participants Interval 37.9 to 50.7	43.8 Percentage of participants Interval 37.2 to 50.4

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 16	37.2 Percentage of participants Interval 31.1 to 43.3	39.5 Percentage of participants Interval 33.3 to 45.7	37.3 Percentage of participants Interval 31.0 to 43.7
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 52	46.0 Percentage of participants Interval 39.1 to 52.9	46.2 Percentage of participants Interval 39.4 to 53.1	51.3 Percentage of participants Interval 44.4 to 58.2
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 96	55.2 Percentage of participants Interval 47.6 to 62.8	44.1 Percentage of participants Interval 36.9 to 51.4	48.8 Percentage of participants Interval 41.1 to 56.4

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with non-missing, valid assessments at Baseline and each timepoint were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 16	12.8 Percentage of participants Interval 9.0 to 16.7	17.0 Percentage of participants Interval 12.7 to 21.4	13.4 Percentage of participants Interval 9.3 to 17.4
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 52	16.3 Percentage of participants Interval 11.7 to 20.8	19.2 Percentage of participants Interval 14.4 to 24.0	19.2 Percentage of participants Interval 14.4 to 24.0
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 96	25.1 Percentage of participants Interval 19.3 to 30.9	19.3 Percentage of participants Interval 14.2 to 24.5	21.8 Percentage of participants Interval 16.3 to 27.2

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 16	14.2 Percentage of participants Interval 9.7 to 18.7	16.6 Percentage of participants Interval 11.8 to 21.4	14.4 Percentage of participants Interval 9.6 to 19.1
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 52	18.9 Percentage of participants Interval 13.4 to 24.4	19.0 Percentage of participants Interval 13.6 to 24.3	21.6 Percentage of participants Interval 15.9 to 27.4
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 96	27.9 Percentage of participants Interval 21.0 to 34.8	19.2 Percentage of participants Interval 13.4 to 25.0	25.7 Percentage of participants Interval 19.0 to 32.4

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with non-missing, valid assessments at Baseline and each timepoint were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 16	3.6 Percentage of participants Interval 1.4 to 5.8	8.3 Percentage of participants Interval 5.2 to 11.5	3.4 Percentage of participants Interval 1.2 to 5.5
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 52	4.1 Percentage of participants Interval 1.6 to 6.5	7.3 Percentage of participants Interval 4.1 to 10.4	4.9 Percentage of participants Interval 2.2 to 7.6
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population Week 96	7.7 Percentage of participants Interval 4.1 to 11.2	7.3 Percentage of participants Interval 4.0 to 10.6	5.3 Percentage of participants Interval 2.3 to 8.4

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 52, and 96

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 16	3.6 Percentage of participants Interval 1.1 to 6.0	6.5 Percentage of participants Interval 3.3 to 9.7	3.3 Percentage of participants Interval 0.9 to 5.8
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 52	5.1 Percentage of participants Interval 2.0 to 8.1	6.3 Percentage of participants Interval 3.0 to 9.7	4.6 Percentage of participants Interval 1.7 to 7.5
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population Week 96	9.2 Percentage of participants Interval 4.8 to 13.7	5.6 Percentage of participants Interval 2.2 to 9.0	6.3 Percentage of participants Interval 2.5 to 10.0

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: ITT Population and Treatment-Naive Population. Only participants with non-missing, valid assessments at Baseline and Week 52 were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=215 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=221 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=221 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations ITT Population	0.8 Percentage of participants Interval 0.0 to 2.0	0.9 Percentage of participants Interval 0.0 to 2.2	0.4 Percentage of participants Interval 0.0 to 1.3
Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations Treatment-Naive Population	0.6 Percentage of participants Interval 0.0 to 1.8	1.2 Percentage of participants Interval 0.0 to 2.8	0.0 Percentage of participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: ITT Population and Treatment-Naive Population. Only participants with non-missing, valid assessments at Baseline and Week 52 were included in the analysis.

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=230 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=250 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=236 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations ITT Population	0.0 Percentage of participants Interval 0.0 to 0.0	0.0 Percentage of participants Interval 0.0 to 0.0	0.0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations Treatment-Naive Population	0.0 Percentage of participants Interval 0.0 to 0.0	0.0 Percentage of participants Interval 0.0 to 0.0	0.0 Percentage of participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Week 52

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 52.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=308 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population Once Every 4 Weeks	13.3 Percentage of participants Interval 9.5 to 17.1	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population Once Every 8 Weeks	15.6 Percentage of participants Interval 11.5 to 19.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population Once Every 12 Weeks	20.1 Percentage of participants Interval 15.6 to 24.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population Once Every 16 Weeks	51.0 Percentage of participants Interval 45.4 to 56.6	—	—

SECONDARY outcome

Timeframe: Week 52

Population: Treatment-Naive Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization. Participants were grouped according to the treatment assigned at randomization. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 52.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=245 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population Once Every 12 Weeks	20.0 Percentage of participants Interval 15.0 to 25.0	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population Once Every 16 Weeks	54.3 Percentage of participants Interval 48.0 to 60.5	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population Once Every 4 Weeks	11.8 Percentage of participants Interval 7.8 to 15.9	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population Once Every 8 Weeks	13.9 Percentage of participants Interval 9.5 to 18.2	—	—

SECONDARY outcome

Timeframe: Week 96

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 96.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=287 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population Once Every 4 Weeks	10.1 Percentage of participants Interval 6.6 to 13.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population Once Every 8 Weeks	11.8 Percentage of participants Interval 8.1 to 15.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population Once Every 12 Weeks	13.6 Percentage of participants Interval 9.6 to 17.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population Once Every 16 Weeks	64.5 Percentage of participants Interval 58.9 to 70.0	—	—

SECONDARY outcome

Timeframe: Week 96

Population: Treatment-Naive Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization. Participants were grouped according to the treatment assigned at randomization. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 96.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=227 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population Once Every 4 Weeks	9.3 Percentage of participants Interval 5.5 to 13.0	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population Once Every 8 Weeks	9.7 Percentage of participants Interval 5.8 to 13.5	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population Once Every 12 Weeks	12.8 Percentage of participants Interval 8.4 to 17.1	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population Once Every 16 Weeks	68.3 Percentage of participants Interval 62.2 to 74.3	—	—

SECONDARY outcome

Timeframe: From start of PTI (Week 12 or later) until Week 52

Population: ITT Population and Treatment-Naive Population. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 52.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=308 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations ITT Population	64.3 Percentage of participants Interval 58.9 to 69.6	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations Treatment-Naive Population	66.9 Percentage of participants Interval 61.0 to 72.8	—	—

SECONDARY outcome

Timeframe: From start of PTI (Week 12 or later) until Week 96

Population: ITT Population and Treatment-Naive Population. The number analyzed includes all participants in Arm B: Faricimab 6 mg PTI who had not discontinued the study prior to Week 96.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=287 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations ITT Population	63.1 Percentage of participants Interval 57.5 to 68.7	—	—
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations Treatment-Naive Population	65.6 Percentage of participants Interval 59.4 to 71.8	—	—

SECONDARY outcome

Timeframe: From Baseline through Week 56

Population: ITT Population and Treatment-Naive Population

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	-195.8 microns Interval -204.1 to -187.5	-187.6 microns Interval -195.8 to -179.5	-170.1 microns Interval -178.3 to -161.8
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	-195.0 microns Interval -204.2 to -185.9	-189.4 microns Interval -198.3 to -180.4	-175.1 microns Interval -184.2 to -165.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 44	-181.7 microns Interval -191.0 to -172.3	-185.9 microns Interval -195.1 to -176.7	-172.3 microns Interval -181.7 to -162.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 48	-195.6 microns Interval -205.0 to -186.2	-184.9 microns Interval -194.1 to -175.8	-162.7 microns Interval -172.0 to -153.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 52	-188.6 microns Interval -197.9 to -179.3	-186.1 microns Interval -195.3 to -177.0	-176.6 microns Interval -185.9 to -167.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 56	-199.0 microns Interval -208.4 to -189.7	-188.5 microns Interval -197.7 to -179.4	-168.2 microns Interval -177.5 to -158.8
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 60	-194.1 microns Interval -204.1 to -184.0	-186.1 microns Interval -195.9 to -176.3	-179.0 microns Interval -189.1 to -168.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 68	-196.2 microns Interval -205.2 to -187.1	-190.3 microns Interval -199.2 to -181.5	-181.4 microns Interval -190.4 to -172.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 72	-202.8 microns Interval -212.3 to -193.4	-191.9 microns Interval -201.2 to -182.6	-172.5 microns Interval -181.9 to -163.0
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 76	-198.8 microns Interval -207.4 to -190.3	-191.3 microns Interval -199.6 to -182.9	-185.4 microns Interval -194.0 to -176.8
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 80	-204.0 microns Interval -213.4 to -194.6	-189.7 microns Interval -198.8 to -180.5	-176.7 microns Interval -186.1 to -167.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 84	-198.2 microns Interval -207.6 to -188.9	-197.9 microns Interval -207.1 to -188.8	-185.5 microns Interval -194.7 to -176.2
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 88	-201.5 microns Interval -211.3 to -191.7	-194.9 microns Interval -204.4 to -185.3	-177.1 microns Interval -186.9 to -167.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 92	-200.5 microns Interval -210.2 to -190.9	-195.4 microns Interval -204.7 to -186.1	-184.0 microns Interval -193.7 to -174.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 96	-206.3 microns Interval -215.7 to -196.8	-199.0 microns Interval -208.2 to -189.7	-180.0 microns Interval -189.5 to -170.5
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 100	-201.1 microns Interval -210.5 to -191.8	-196.9 microns Interval -206.0 to -187.8	-192.8 microns Interval -202.2 to -183.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 16	-162.2 microns Interval -170.4 to -154.0	-167.1 microns Interval -175.2 to -158.9	-151.4 microns Interval -159.7 to -143.2
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 4	-106.1 microns Interval -115.7 to -96.6	-113.9 microns Interval -123.4 to -104.4	-107.3 microns Interval -116.8 to -97.7
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 8	-132.0 microns Interval -140.9 to -123.0	-139.6 microns Interval -148.4 to -130.8	-129.6 microns Interval -138.5 to -120.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 12	-146.0 microns Interval -154.8 to -137.2	-155.0 microns Interval -163.7 to -146.3	-143.1 microns Interval -151.9 to -134.2
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 20	-166.8 microns Interval -176.0 to -157.6	-157.2 microns Interval -166.3 to -148.1	-154.6 microns Interval -163.8 to -145.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 24	-179.9 microns Interval -188.4 to -171.3	-181.4 microns Interval -189.8 to -173.0	-146.6 microns Interval -155.1 to -138.1
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 28	-164.8 microns Interval -173.2 to -156.5	-184.0 microns Interval -192.3 to -175.8	-165.0 microns Interval -173.3 to -156.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 32	-181.9 microns Interval -191.4 to -172.4	-169.4 microns Interval -178.9 to -160.0	-154.8 microns Interval -164.3 to -145.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 36	-170.9 microns Interval -179.8 to -162.1	-189.2 microns Interval -197.9 to -180.5	-168.6 microns Interval -177.4 to -159.7
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 40	-191.6 microns Interval -200.9 to -182.3	-183.8 microns Interval -193.0 to -174.6	-160.0 microns Interval -169.3 to -150.7
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population Week 64	-197.2 microns Interval -206.7 to -187.8	-189.8 microns Interval -199.0 to -180.7	-172.1 microns Interval -181.5 to -162.8

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: Treatment-Naive (TN) Population: all participants randomized in the study who had not received any intravitreal anti-VEGF agents in the study eye prior to randomization, grouped according to the treatment assigned at randomization. One participant in Arm B: Faricimab 6 mg PTI was excluded from the TN Population for the final analysis due to a late report of prior anti-VEGF treatment.

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=254 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=254 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=248 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 4	-106.3 microns Interval -116.9 to -95.6	-112.9 microns Interval -123.5 to -102.3	-106.3 microns Interval -117.0 to -95.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 8	-131.8 microns Interval -141.6 to -122.0	-140.6 microns Interval -150.3 to -130.9	-130.4 microns Interval -140.2 to -120.5
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 12	-148.8 microns Interval -158.4 to -139.2	-156.6 microns Interval -166.2 to -147.1	-145.3 microns Interval -154.9 to -135.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 16	-163.0 microns Interval -171.9 to -154.0	-168.8 microns Interval -177.7 to -159.9	-157.0 microns Interval -166.0 to -148.0
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 20	-170.5 microns Interval -180.1 to -160.9	-162.3 microns Interval -171.9 to -152.8	-160.6 microns Interval -170.2 to -150.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 24	-182.4 microns Interval -191.5 to -173.3	-182.9 microns Interval -191.9 to -173.9	-154.6 microns Interval -163.8 to -145.5
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 28	-166.8 microns Interval -175.9 to -157.8	-183.9 microns Interval -192.9 to -174.9	-174.2 microns Interval -183.2 to -165.1
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 32	-183.7 microns Interval -194.0 to -173.4	-168.0 microns Interval -178.2 to -157.7	-161.0 microns Interval -171.4 to -150.7
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 36	-173.8 microns Interval -183.5 to -164.1	-191.5 microns Interval -201.1 to -182.0	-175.6 microns Interval -185.2 to -165.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 40	-191.6 microns Interval -201.9 to -181.4	-186.9 microns Interval -197.0 to -176.8	-165.6 microns Interval -175.8 to -155.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 44	-181.4 microns Interval -191.7 to -171.1	-188.9 microns Interval -199.1 to -178.8	-177.6 microns Interval -187.9 to -167.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 48	-194.5 microns Interval -205.1 to -184.0	-186.8 microns Interval -197.1 to -176.6	-165.8 microns Interval -176.3 to -155.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 52	-188.7 microns Interval -198.8 to -178.7	-186.6 microns Interval -196.5 to -176.8	-181.3 microns Interval -191.4 to -171.3
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 56	-196.7 microns Interval -207.0 to -186.4	-189.9 microns Interval -200.0 to -179.8	-174.0 microns Interval -184.3 to -163.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 60	-194.3 microns Interval -205.6 to -183.0	-185.2 microns Interval -196.3 to -174.1	-184.1 microns Interval -195.5 to -172.7
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 64	-196.5 microns Interval -207.3 to -185.6	-191.2 microns Interval -201.7 to -180.7	-175.6 microns Interval -186.5 to -164.8
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 68	-194.6 microns Interval -204.4 to -184.8	-192.7 microns Interval -202.3 to -183.1	-186.3 microns Interval -196.1 to -176.5
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 72	-200.9 microns Interval -211.0 to -190.8	-193.4 microns Interval -203.3 to -183.5	-178.0 microns Interval -188.1 to -167.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 76	-200.2 microns Interval -209.6 to -190.8	-192.0 microns Interval -201.2 to -182.9	-190.2 microns Interval -199.7 to -180.8
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 80	-202.6 microns Interval -212.9 to -192.4	-190.0 microns Interval -199.9 to -180.1	-182.6 microns Interval -192.8 to -172.4
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 84	-199.3 microns Interval -209.8 to -188.7	-196.0 microns Interval -206.3 to -185.8	-189.5 microns Interval -200.0 to -179.0
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 88	-200.3 microns Interval -211.3 to -189.4	-195.6 microns Interval -206.2 to -184.9	-181.9 microns Interval -192.8 to -170.9
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 92	-199.3 microns Interval -209.9 to -188.7	-196.0 microns Interval -206.3 to -185.8	-187.2 microns Interval -197.8 to -176.6
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 96	-204.5 microns Interval -215.1 to -193.8	-200.8 microns Interval -211.1 to -190.4	-182.9 microns Interval -193.5 to -172.2
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population Week 100	-200.9 microns Interval -211.1 to -190.6	-198.7 microns Interval -208.6 to -188.8	-193.5 microns Interval -203.8 to -183.2

SECONDARY outcome

Timeframe: Average of Weeks 48, 52, and 56

Population: ITT Population and Treatment-Naive Population. Only participants with at least one non-missing, valid assessment at Weeks 48, 52, or 56 were included in the analysis.

Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of <325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=268 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=294 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=279 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations ITT Population	85.5 Percentage of participants Interval 81.3 to 89.7	81.5 Percentage of participants Interval 77.1 to 85.9	73.2 Percentage of participants Interval 68.0 to 78.3
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations Treatment-Naive Population	86.0 Percentage of participants Interval 81.3 to 90.7	83.2 Percentage of participants Interval 78.4 to 88.0	77.0 Percentage of participants Interval 71.3 to 82.6

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Absence of diabetic macular edema was defined as achieving a central subfield thickness of <325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 4	38.2 Percentage of participants Interval 32.8 to 43.6	43.5 Percentage of participants Interval 38.0 to 49.0	38.1 Percentage of participants Interval 32.8 to 43.5
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 8	53.3 Percentage of participants Interval 47.7 to 58.9	57.3 Percentage of participants Interval 51.9 to 62.7	47.9 Percentage of participants Interval 42.4 to 53.5
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 12	61.8 Percentage of participants Interval 56.5 to 67.2	64.8 Percentage of participants Interval 59.4 to 70.1	56.4 Percentage of participants Interval 50.8 to 62.0
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 16	69.2 Percentage of participants Interval 64.0 to 74.4	69.1 Percentage of participants Interval 63.9 to 74.2	62.3 Percentage of participants Interval 56.8 to 67.8
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 20	73.8 Percentage of participants Interval 68.9 to 78.8	67.2 Percentage of participants Interval 62.0 to 72.4	67.4 Percentage of participants Interval 62.1 to 72.7
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 24	77.7 Percentage of participants Interval 73.0 to 82.4	77.9 Percentage of participants Interval 73.2 to 82.5	62.4 Percentage of participants Interval 57.0 to 67.9
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 28	72.1 Percentage of participants Interval 67.0 to 77.3	81.2 Percentage of participants Interval 76.8 to 85.6	71.2 Percentage of participants Interval 66.1 to 76.4
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 32	80.2 Percentage of participants Interval 75.6 to 84.9	72.1 Percentage of participants Interval 67.0 to 77.3	67.0 Percentage of participants Interval 61.5 to 72.4
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 36	73.8 Percentage of participants Interval 68.7 to 79.0	83.8 Percentage of participants Interval 79.5 to 88.1	74.6 Percentage of participants Interval 69.6 to 79.7
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 40	86.1 Percentage of participants Interval 82.1 to 90.2	81.5 Percentage of participants Interval 77.0 to 86.0	72.1 Percentage of participants Interval 66.9 to 77.3
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 44	81.5 Percentage of participants Interval 76.9 to 86.0	80.3 Percentage of participants Interval 75.7 to 84.9	76.6 Percentage of participants Interval 71.6 to 81.6
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 48	87.5 Percentage of participants Interval 83.4 to 91.6	82.7 Percentage of participants Interval 78.4 to 87.1	71.0 Percentage of participants Interval 65.7 to 76.4
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 52	83.7 Percentage of participants Interval 79.3 to 88.2	82.1 Percentage of participants Interval 77.6 to 86.6	76.4 Percentage of participants Interval 71.5 to 81.4
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 56	89.5 Percentage of participants Interval 85.9 to 93.2	85.4 Percentage of participants Interval 81.4 to 89.5	72.2 Percentage of participants Interval 66.9 to 77.6
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 60	85.4 Percentage of participants Interval 81.1 to 89.6	86.1 Percentage of participants Interval 82.0 to 90.1	78.8 Percentage of participants Interval 73.9 to 83.8
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 64	87.6 Percentage of participants Interval 83.5 to 91.7	82.8 Percentage of participants Interval 78.5 to 87.2	73.8 Percentage of participants Interval 68.5 to 79.0
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 68	85.0 Percentage of participants Interval 80.6 to 89.3	83.2 Percentage of participants Interval 78.8 to 87.6	78.2 Percentage of participants Interval 73.1 to 83.2
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 72	88.9 Percentage of participants Interval 85.1 to 92.8	82.4 Percentage of participants Interval 77.8 to 86.9	74.6 Percentage of participants Interval 69.2 to 80.0
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 76	88.4 Percentage of participants Interval 84.6 to 92.3	82.2 Percentage of participants Interval 77.7 to 86.7	79.3 Percentage of participants Interval 74.3 to 84.4
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 80	90.0 Percentage of participants Interval 86.3 to 93.8	83.4 Percentage of participants Interval 78.9 to 87.8	76.6 Percentage of participants Interval 71.4 to 81.9
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 84	88.2 Percentage of participants Interval 84.2 to 92.2	85.8 Percentage of participants Interval 81.6 to 90.0	80.3 Percentage of participants Interval 75.4 to 85.2
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 88	89.5 Percentage of participants Interval 85.9 to 93.2	85.0 Percentage of participants Interval 80.7 to 89.2	78.8 Percentage of participants Interval 73.8 to 83.9
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 92	88.4 Percentage of participants Interval 84.5 to 92.4	84.6 Percentage of participants Interval 80.3 to 88.9	80.3 Percentage of participants Interval 75.3 to 85.3
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 96	92.7 Percentage of participants Interval 89.5 to 95.8	88.1 Percentage of participants Interval 84.2 to 92.0	80.0 Percentage of participants Interval 74.9 to 85.0
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population Week 100	90.6 Percentage of participants Interval 87.0 to 94.2	85.5 Percentage of participants Interval 81.3 to 89.7	84.2 Percentage of participants Interval 79.6 to 88.8

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of <280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 12	33.1 Percentage of participants Interval 27.9 to 38.3	36.7 Percentage of participants Interval 31.3 to 42.0	28.2 Percentage of participants Interval 23.2 to 33.3
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 16	38.5 Percentage of participants Interval 33.1 to 44.0	45.0 Percentage of participants Interval 39.4 to 50.5	33.4 Percentage of participants Interval 28.0 to 38.8
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 20	44.3 Percentage of participants Interval 38.7 to 49.9	41.0 Percentage of participants Interval 35.5 to 46.5	38.5 Percentage of participants Interval 32.9 to 44.0
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 24	50.2 Percentage of participants Interval 44.6 to 55.8	52.3 Percentage of participants Interval 46.8 to 57.9	37.0 Percentage of participants Interval 31.5 to 42.4
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 28	45.2 Percentage of participants Interval 39.5 to 50.8	51.9 Percentage of participants Interval 46.4 to 57.3	46.0 Percentage of participants Interval 40.3 to 51.8
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 32	52.3 Percentage of participants Interval 46.6 to 58.1	46.6 Percentage of participants Interval 41.0 to 52.3	42.7 Percentage of participants Interval 36.9 to 48.4
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 40	61.2 Percentage of participants Interval 55.5 to 66.8	57.7 Percentage of participants Interval 52.0 to 63.3	49.4 Percentage of participants Interval 43.6 to 55.2
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 36	50.0 Percentage of participants Interval 44.2 to 55.7	59.6 Percentage of participants Interval 54.0 to 65.1	48.8 Percentage of participants Interval 42.9 to 54.6
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 4	12.3 Percentage of participants Interval 8.7 to 16.0	18.5 Percentage of participants Interval 14.2 to 22.8	15.0 Percentage of participants Interval 11.0 to 18.9
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 8	26.2 Percentage of participants Interval 21.3 to 31.0	25.9 Percentage of participants Interval 21.1 to 30.8	22.5 Percentage of participants Interval 17.9 to 27.2
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 44	59.9 Percentage of participants Interval 54.3 to 65.5	58.6 Percentage of participants Interval 53.0 to 64.1	53.5 Percentage of participants Interval 47.7 to 59.4
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 48	67.5 Percentage of participants Interval 61.7 to 73.2	58.3 Percentage of participants Interval 52.8 to 63.8	50.2 Percentage of participants Interval 44.3 to 56.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 52	64.5 Percentage of participants Interval 58.8 to 70.1	60.9 Percentage of participants Interval 55.3 to 66.4	54.2 Percentage of participants Interval 48.4 to 60.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 56	70.3 Percentage of participants Interval 64.9 to 75.6	63.6 Percentage of participants Interval 58.2 to 69.1	51.2 Percentage of participants Interval 45.2 to 57.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 60	65.4 Percentage of participants Interval 59.8 to 71.1	65.7 Percentage of participants Interval 60.1 to 71.2	59.2 Percentage of participants Interval 53.3 to 65.2
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 64	71.6 Percentage of participants Interval 66.2 to 77.1	58.7 Percentage of participants Interval 53.1 to 64.2	52.8 Percentage of participants Interval 46.8 to 58.7
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 68	66.9 Percentage of participants Interval 61.2 to 72.6	60.6 Percentage of participants Interval 55.0 to 66.2	59.8 Percentage of participants Interval 53.9 to 65.8
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 72	71.2 Percentage of participants Interval 65.6 to 76.7	65.6 Percentage of participants Interval 60.1 to 71.1	58.8 Percentage of participants Interval 52.8 to 64.8
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 76	68.4 Percentage of participants Interval 62.9 to 74.0	62.8 Percentage of participants Interval 57.2 to 68.5	58.9 Percentage of participants Interval 52.9 to 64.9
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 80	72.6 Percentage of participants Interval 67.2 to 78.1	64.0 Percentage of participants Interval 58.4 to 69.7	60.1 Percentage of participants Interval 54.1 to 66.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 84	68.4 Percentage of participants Interval 62.8 to 74.0	67.6 Percentage of participants Interval 62.1 to 73.1	60.7 Percentage of participants Interval 54.7 to 66.6
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 88	71.8 Percentage of participants Interval 66.4 to 77.2	63.3 Percentage of participants Interval 57.7 to 68.9	60.3 Percentage of participants Interval 54.2 to 66.4
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 92	72.9 Percentage of participants Interval 67.5 to 78.3	64.6 Percentage of participants Interval 59.0 to 70.2	64.0 Percentage of participants Interval 58.0 to 70.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 96	75.1 Percentage of participants Interval 69.9 to 80.3	67.4 Percentage of participants Interval 62.0 to 72.9	63.1 Percentage of participants Interval 57.0 to 69.1
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population Week 100	72.0 Percentage of participants Interval 66.6 to 77.4	69.3 Percentage of participants Interval 63.9 to 74.6	64.8 Percentage of participants Interval 58.8 to 70.9

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 16	19.6 Percentage of participants Interval 15.1 to 24.1	19.8 Percentage of participants Interval 15.4 to 24.2	13.3 Percentage of participants Interval 9.4 to 17.1
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 48	40.9 Percentage of participants Interval 34.8 to 47.0	32.3 Percentage of participants Interval 26.9 to 37.7	22.5 Percentage of participants Interval 17.6 to 27.3
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 52	39.1 Percentage of participants Interval 33.3 to 44.9	35.9 Percentage of participants Interval 30.3 to 41.5	28.4 Percentage of participants Interval 23.1 to 33.7
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 56	42.5 Percentage of participants Interval 36.6 to 48.3	39.9 Percentage of participants Interval 34.2 to 45.6	27.3 Percentage of participants Interval 22.0 to 32.7
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 92	56.0 Percentage of participants Interval 49.8 to 62.2	45.0 Percentage of participants Interval 39.0 to 51.0	39.2 Percentage of participants Interval 33.0 to 45.4
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 96	62.3 Percentage of participants Interval 56.3 to 68.4	47.6 Percentage of participants Interval 41.5 to 53.6	39.1 Percentage of participants Interval 32.8 to 45.3
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population Week 100	56.6 Percentage of participants Interval 50.4 to 62.8	52.2 Percentage of participants Interval 46.2 to 58.1	45.1 Percentage of participants Interval 38.7 to 51.4

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 16	99.0 Percentage of participants Interval 97.9 to 100.0	96.7 Percentage of participants Interval 94.7 to 98.7	95.6 Percentage of participants Interval 93.3 to 97.8
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 48	97.2 Percentage of participants Interval 95.1 to 99.2	95.8 Percentage of participants Interval 93.5 to 98.1	95.3 Percentage of participants Interval 92.8 to 97.8
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 52	94.7 Percentage of participants Interval 91.9 to 97.4	95.7 Percentage of participants Interval 93.4 to 98.0	97.8 Percentage of participants Interval 96.1 to 99.5
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 56	97.0 Percentage of participants Interval 95.0 to 99.0	95.8 Percentage of participants Interval 93.5 to 98.1	95.9 Percentage of participants Interval 93.5 to 98.2
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 92	95.0 Percentage of participants Interval 92.3 to 97.8	96.2 Percentage of participants Interval 93.9 to 98.5	96.0 Percentage of participants Interval 93.5 to 98.4
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 96	96.3 Percentage of participants Interval 94.0 to 98.7	96.6 Percentage of participants Interval 94.5 to 98.8	96.2 Percentage of participants Interval 93.8 to 98.6
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population Week 100	96.0 Percentage of participants Interval 93.5 to 98.4	96.2 Percentage of participants Interval 93.9 to 98.5	95.9 Percentage of participants Interval 93.5 to 98.3

SECONDARY outcome

Timeframe: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At each timepoint, only participants with non-missing, valid assessments were included in the analysis.

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. <64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 16	19.6 Percentage of participants Interval 15.1 to 24.1	19.1 Percentage of participants Interval 14.8 to 23.5	13.3 Percentage of participants Interval 9.4 to 17.1
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 48	40.5 Percentage of participants Interval 34.4 to 46.6	31.2 Percentage of participants Interval 25.8 to 36.6	22.5 Percentage of participants Interval 17.6 to 27.3
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 52	39.1 Percentage of participants Interval 33.3 to 44.9	34.9 Percentage of participants Interval 29.4 to 40.5	28.4 Percentage of participants Interval 23.1 to 33.7
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 56	42.3 Percentage of participants Interval 36.4 to 48.2	39.2 Percentage of participants Interval 33.5 to 44.9	26.6 Percentage of participants Interval 21.3 to 31.8
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 92	55.2 Percentage of participants Interval 49.0 to 61.4	44.2 Percentage of participants Interval 38.2 to 50.2	38.3 Percentage of participants Interval 32.2 to 44.5
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 96	61.0 Percentage of participants Interval 54.9 to 67.2	46.5 Percentage of participants Interval 40.4 to 52.5	38.2 Percentage of participants Interval 32.0 to 44.4
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population Week 100	54.9 Percentage of participants Interval 48.7 to 61.2	51.2 Percentage of participants Interval 45.2 to 57.2	44.8 Percentage of participants Interval 38.4 to 51.2

SECONDARY outcome

Timeframe: Baseline, Weeks 24, 52, and 100

Population: ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.

The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=315 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population Week 24	5.7 score on a scale Interval 4.6 to 6.9	6.5 score on a scale Interval 5.4 to 7.7	7.0 score on a scale Interval 5.9 to 8.1
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population Week 52	6.8 score on a scale Interval 5.5 to 8.2	6.6 score on a scale Interval 5.3 to 7.9	7.6 score on a scale Interval 6.3 to 9.0
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population Week 100	8.8 score on a scale Interval 7.3 to 10.3	7.3 score on a scale Interval 5.9 to 8.7	6.9 score on a scale Interval 5.4 to 8.4

SECONDARY outcome

Timeframe: From first dose of study drug through end of study (up to 2 years)

Population: The safety-evaluable population comprised all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye.

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=314 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With at Least One Adverse Event Adverse Event (AE)	89.3 Percentage of participants	85.3 Percentage of participants	87.3 Percentage of participants
Percentage of Participants With at Least One Adverse Event Serious AE (SAE)	30.6 Percentage of participants	25.7 Percentage of participants	31.8 Percentage of participants
Percentage of Participants With at Least One Adverse Event AE Leading to Withdrawal from Study Treatment	2.2 Percentage of participants	2.8 Percentage of participants	1.6 Percentage of participants
Percentage of Participants With at Least One Adverse Event AE of Special Interest (AESI)	7.6 Percentage of participants	7.2 Percentage of participants	6.4 Percentage of participants

SECONDARY outcome

Timeframe: From first dose of study drug through end of study (up to 2 years)

Population: The safety-evaluable population comprised all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye.

This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=314 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: Adverse Event (AE)	52.4 Percentage of participants	51.7 Percentage of participants	44.6 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: Serious AE (SAE)	4.4 Percentage of participants	6.3 Percentage of participants	4.1 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: AE Leading to Withdrawal from Treatment	0.3 Percentage of participants	1.9 Percentage of participants	0.3 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: Treatment-related AE	3.2 Percentage of participants	4.4 Percentage of participants	4.8 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: Treatment-related SAE	0.0 Percentage of participants	0.9 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: AE of Special Interest (AESI)	4.4 Percentage of participants	6.3 Percentage of participants	3.8 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: AESI, Drop in Visual Acuity (VA) Score ≥30 Letters	3.2 Percentage of participants	5.0 Percentage of participants	2.9 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: AESI, Associated with Severe Intraocular Inflammation (IOI)	0.3 Percentage of participants	0.0 Percentage of participants	0.3 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss	0.9 Percentage of participants	1.3 Percentage of participants	1.0 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: AE	50.5 Percentage of participants	43.3 Percentage of participants	44.3 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: SAE	3.5 Percentage of participants	1.9 Percentage of participants	3.5 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: AESI	3.8 Percentage of participants	0.9 Percentage of participants	2.9 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: AESI, Drop in VA Score ≥30 Letters	3.5 Percentage of participants	0.6 Percentage of participants	2.5 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: AESI, Associated with Severe IOI	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss	0.3 Percentage of participants	0.3 Percentage of participants	0.3 Percentage of participants

SECONDARY outcome

Timeframe: From first dose of study drug through end of study (up to 2 years)

Population: The safety-evaluable population comprised all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye.

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=317 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=314 Participants Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants With at Least One Non-Ocular Adverse Event Adverse Event (AE)	69.4 Percentage of participants	68.3 Percentage of participants	73.6 Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event Serious AE (SAE)	24.0 Percentage of participants	20.1 Percentage of participants	28.3 Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event AE Leading to Withdrawal from Study Treatment	1.9 Percentage of participants	0.9 Percentage of participants	1.3 Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event AE of Special Interest (AESI)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants

SECONDARY outcome

Timeframe: Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100

Population: This analysis only included participants in Arms A and B who received treatment with faricimab and with at least one plasma sample, provided sufficient dosing information (dose and dosing time) was available. The number of participants analyzed at a given timepoint includes those with an available plasma sample and dosing information at that timepoint.

Faricimab concentration in plasma was determined using a validated immunoassay method.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=315 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Plasma Concentration of Faricimab Over Time Week 100	0.0058 micrograms per millilitre (μg/mL) Standard Deviation 0.0106	0.0071 micrograms per millilitre (μg/mL) Standard Deviation 0.0110	—
Plasma Concentration of Faricimab Over Time Baseline	0.0001 micrograms per millilitre (μg/mL) Standard Deviation 0.0020	0.0000 micrograms per millilitre (μg/mL) Standard Deviation 0.0004	—
Plasma Concentration of Faricimab Over Time Week 4	0.0192 micrograms per millilitre (μg/mL) Standard Deviation 0.0163	0.0196 micrograms per millilitre (μg/mL) Standard Deviation 0.0151	—
Plasma Concentration of Faricimab Over Time Week 28	0.0030 micrograms per millilitre (μg/mL) Standard Deviation 0.0050	0.0115 micrograms per millilitre (μg/mL) Standard Deviation 0.0189	—
Plasma Concentration of Faricimab Over Time Week 52	0.0042 micrograms per millilitre (μg/mL) Standard Deviation 0.0078	0.0113 micrograms per millilitre (μg/mL) Standard Deviation 0.0140	—
Plasma Concentration of Faricimab Over Time Week 76	0.0060 micrograms per millilitre (μg/mL) Standard Deviation 0.0093	0.0060 micrograms per millilitre (μg/mL) Standard Deviation 0.0103	—

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 28, 52, 76, and 100

Population: The analysis population consisted of all participants receiving faricimab with at least one determinant post-baseline ADA assessment.

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

Outcome measures

Measure	A: Faricimab 6 mg Q8W n=313 Participants Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=318 Participants Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study Total Treatment-Emergent ADA-Positive	7.0 Percentage of participants	8.2 Percentage of participants	—
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study Treatment-Induced ADA-Positive	7.0 Percentage of participants	8.2 Percentage of participants	—
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study Treatment-Boosted ADA-Positive	0.0 Percentage of participants	0.0 Percentage of participants	—

Adverse Events

A: Faricimab 6 mg Q8W

Serious events: 97 serious events

Other events: 195 other events

Deaths: 12 deaths

B: Faricimab 6 mg PTI

Serious events: 82 serious events

Other events: 169 other events

Deaths: 9 deaths

C: Aflibercept 2 mg Q8W

Serious events: 100 serious events

Other events: 178 other events

Deaths: 10 deaths

Serious adverse events

Measure	A: Faricimab 6 mg Q8W n=317 participants at risk Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 participants at risk Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=314 participants at risk Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Blood and lymphatic system disorders Anaemia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Blood and lymphatic system disorders Microcytic anaemia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Acute coronary syndrome	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Acute myocardial infarction	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Angina pectoris	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Angina unstable	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Aortic valve stenosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Atrial fibrillation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardiac arrest	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardiac failure	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.94% 3/319 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/314 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardiac failure acute	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardiac failure chronic	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardiac failure congestive	2.5% 8/317 • Number of events 10 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/319 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Coronary artery disease	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Ischaemic cardiomyopathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Myocardial infarction	1.6% 5/317 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.94% 3/319 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/314 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Myocardial ischaemia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Right ventricular failure	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Subendocardial ischaemia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Cataract	1.3% 4/317 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.2% 7/319 • Number of events 7 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.2% 7/314 • Number of events 7 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Cataract subcapsular	0.32% 1/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Diabetic retinal oedema	2.2% 7/317 • Number of events 10 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Diabetic retinopathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Dry eye	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Eye haemorrhage	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Macular fibrosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Retinal tear	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Retinal vein occlusion	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Visual acuity reduced	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Visual impairment	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Vitreous haemorrhage	1.3% 4/317 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Colitis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Gastrointestinal dysplasia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Impaired gastric emptying	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Chest pain	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Inflammation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Multiple organ dysfunction syndrome	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Necrosis	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Pyrexia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Soft tissue inflammation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Hepatobiliary disorders Bile duct stenosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Hepatobiliary disorders Cholecystitis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Hepatobiliary disorders Cholelithiasis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Immune system disorders Anaphylactic reaction	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Immune system disorders Hypersensitivity	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Anal abscess	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Arthritis bacterial	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations COVID-19 pneumonia	0.95% 3/317 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Cellulitis	0.95% 3/317 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.5% 8/314 • Number of events 8 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Cellulitis gangrenous	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Cystitis	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Diabetic foot infection	1.3% 4/317 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Diabetic gangrene	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Diverticulitis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Endocarditis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Endophthalmitis	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Escherichia sepsis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Gallbladder empyema	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Gangrene	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Gastroenteritis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Influenza	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Osteomyelitis	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Pneumonia	2.2% 7/317 • Number of events 7 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.9% 6/319 • Number of events 6 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.6% 5/314 • Number of events 6 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Pyelonephritis	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Respiratory tract infection	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Sepsis	1.6% 5/317 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Upper respiratory tract infection	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Urinary tract infection	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.6% 5/314 • Number of events 6 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Chemical burns of eye	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Fall	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Femoral neck fracture	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Fracture displacement	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Limb injury	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Nail avulsion	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Investigations Blood glucose fluctuation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Investigations Intraocular pressure increased	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Dehydration	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Diabetic endorgan damage	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 7 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Gout	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Hypoglycaemia	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.94% 3/319 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Type 1 diabetes mellitus	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Musculoskeletal and connective tissue disorders Neuropathic arthropathy	0.32% 1/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Musculoskeletal and connective tissue disorders Spondylitis	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hairy cell leukaemia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.32% 1/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Cauda equina syndrome	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Cerebral haemorrhage	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Cerebral infarction	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Cerebrovascular accident	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/314 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Cervical radiculopathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Guillain-Barre syndrome	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Lacunar stroke	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Metabolic encephalopathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Spinal cord compression	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Syncope	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Transient ischaemic attack	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Psychiatric disorders Delirium	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Psychiatric disorders Depression	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Acute kidney injury	1.3% 4/317 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/319 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/314 • Number of events 5 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Azotaemia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Calculus urinary	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Chronic kidney disease	1.3% 4/317 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Diabetic nephropathy	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders End stage renal disease	0.95% 3/317 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Renal cyst	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Renal failure	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Urinary tract inflammation	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.63% 2/317 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/319 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Skin and subcutaneous tissue disorders Diabetic foot	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Arterial occlusive disease	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Deep vein thrombosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Extremity necrosis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Hypertension	0.63% 2/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Hypertensive crisis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Hypertensive urgency	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Hypotension	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.63% 2/319 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Orthostatic hypotension	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Peripheral arterial occlusive disease	0.32% 1/317 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Peripheral vascular disorder	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Blood and lymphatic system disorders Lymphadenopathy mediastinal	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Atrioventricular block complete	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Cardio-respiratory arrest	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Chronic left ventricular failure	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Cardiac disorders Hypertensive heart disease	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Endocrine disorders Hyperplasia adrenal	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Angle closure glaucoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Cataract nuclear	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Diabetic eye disease	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Iridocyclitis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Open angle glaucoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Optic ischaemic neuropathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Posterior capsule opacification	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Retinal artery occlusion	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Retinal degeneration	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Vitreous detachment	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Anorectal varices	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Intra-abdominal haematoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Gastrointestinal disorders Oesophageal varices haemorrhage	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Asthenia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Death	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Generalised oedema	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Hernia obstructive	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
General disorders Peripheral swelling	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Bacteraemia	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations COVID-19	1.9% 6/317 • Number of events 6 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.2% 7/319 • Number of events 8 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	1.3% 4/314 • Number of events 4 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Gastroenteritis viral	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.64% 2/314 • Number of events 2 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Kidney infection	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Localised infection	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Lower respiratory tract infection	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Lyme disease	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Nasopharyngitis	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Osteomyelitis chronic	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Pneumonia viral	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Pyoderma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Septic shock	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Postoperative ileus	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Thermal burn	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Tibia fracture	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Investigations Biopsy bladder	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Investigations SARS-CoV-2 test positive	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Diabetic metabolic decompensation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Musculoskeletal and connective tissue disorders Pain in extremity	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma stage II	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer metastatic	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic neoplasm	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Encephalopathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Ischaemic stroke	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Lacunar infarction	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Leukoencephalopathy	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Monoplegia	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Status epilepticus	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Psychiatric disorders Anxiety	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Psychiatric disorders Confusional state	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Psychiatric disorders Suicide attempt	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Haematuria	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Nephropathy	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Renal and urinary disorders Renal impairment	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Surgical and medical procedures Haemodialysis	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.32% 1/314 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Surgical and medical procedures Hospitalisation	0.32% 1/317 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/319 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Haematoma	0.00% 0/317 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.31% 1/319 • Number of events 1 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.00% 0/314 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.

Other adverse events

Measure	A: Faricimab 6 mg Q8W n=317 participants at risk Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.	B: Faricimab 6 mg PTI n=319 participants at risk Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.	C: Aflibercept 2 mg Q8W n=314 participants at risk Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
Eye disorders Cataract	16.4% 52/317 • Number of events 77 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	18.2% 58/319 • Number of events 88 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	10.5% 33/314 • Number of events 48 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Conjunctival haemorrhage	11.4% 36/317 • Number of events 44 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	7.5% 24/319 • Number of events 29 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	8.0% 25/314 • Number of events 34 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Diabetic retinal oedema	9.1% 29/317 • Number of events 31 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	7.8% 25/319 • Number of events 30 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	7.3% 23/314 • Number of events 27 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Vitreous detachment	6.0% 19/317 • Number of events 26 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	5.6% 18/319 • Number of events 21 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	8.6% 27/314 • Number of events 30 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Nasopharyngitis	9.5% 30/317 • Number of events 35 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	8.5% 27/319 • Number of events 34 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	12.1% 38/314 • Number of events 43 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Infections and infestations Urinary tract infection	4.4% 14/317 • Number of events 20 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	4.7% 15/319 • Number of events 18 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	8.6% 27/314 • Number of events 35 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Nervous system disorders Headache	5.7% 18/317 • Number of events 36 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	3.4% 11/319 • Number of events 16 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.5% 8/314 • Number of events 10 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Vascular disorders Hypertension	6.3% 20/317 • Number of events 22 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	8.2% 26/319 • Number of events 29 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	5.1% 16/314 • Number of events 16 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Dry eye	6.0% 19/317 • Number of events 34 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	6.9% 22/319 • Number of events 39 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	3.5% 11/314 • Number of events 24 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Eye disorders Vitreous floaters	5.4% 17/317 • Number of events 22 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	3.8% 12/319 • Number of events 15 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	5.7% 18/314 • Number of events 21 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Injury, poisoning and procedural complications Fall	5.7% 18/317 • Number of events 23 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.5% 8/319 • Number of events 8 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	4.5% 14/314 • Number of events 19 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Investigations Intraocular pressure increased	6.6% 21/317 • Number of events 34 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	4.4% 14/319 • Number of events 23 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	4.8% 15/314 • Number of events 27 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Musculoskeletal and connective tissue disorders Back pain	5.4% 17/317 • Number of events 17 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	2.2% 7/319 • Number of events 7 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	0.96% 3/314 • Number of events 3 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.
Respiratory, thoracic and mediastinal disorders Cough	4.7% 15/317 • Number of events 15 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	5.0% 16/319 • Number of events 17 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.	3.2% 10/314 • Number of events 10 • From Baseline until Week 100 Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800-821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER